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Abstract. 
 
Mutations of presenilin 1 (PS1) causing 
Alzheimer’s disease selectively increase the secretion 
of the amyloidogenic 
 
b
 
A4(1-42), whereas knocking out 
the gene results in decreased production of both 
 
b
 
A4(1-40) and (1-42) amyloid peptides (De Strooper et 
al., 1998). Therefore, PS1 function is closely linked to 
the 
 
g
 
-secretase processing of the amyloid precursor 
protein (APP). Given the ongoing controversy on the 
subcellular localization of PS1, it remains unclear at 
what level of the secretory and endocytic pathways PS1 
exerts its activity on APP and on the APP carboxy-ter-
minal fragments that are the direct substrates for 
 
g
 
-sec-
retase. Therefore, we have reinvestigated the subcellu-
lar localization of endogenously expressed PS1 in 
neurons in vitro and in vivo using confocal microscopy 
and ﬁne-tuned subcellular fractionation. We show that 
uncleaved PS1 holoprotein is recovered in the nuclear 
envelope fraction, whereas the cleaved PS fragments 
are found mainly in post-ER membranes including the 
intermediate compartment (IC). PS1 is concentrated in 
discrete sec23p- and p58/ERGIC-53–positive patches, 
suggesting its localization in subdomains involved in 
ER export. PS1 is not found to signiﬁcant amounts be-
yond the cis-Golgi. Surprisingly, we found that APP 
carboxy-terminal fragments also coenrich in the pre-
Golgi membrane fractions, consistent with the idea that 
these fragments are the real substrates for 
 
g
 
-secretase. 
Functional evidence that PS1 exerts its effects on
 
g
 
-secretase processing of APP in the ER/IC was ob-
tained using a series of APP trafﬁcking mutants. These 
mutants were investigated in hippocampal neurons de-
rived from transgenic mice expressing PS1wt or PS1 
containing clinical mutations (PS1
 
M146L
 
 and PS1
 
L286V
 
) at 
physiologically relevant levels. We demonstrate that the 
APP-London and PS1 mutations have additive effects 
on the increased secretion of 
 
b
 
A4(1-42) relative to 
 
b
 
A4(1-40), indicating that both mutations operate in-
dependently. Overall, our data clearly establish that 
PS1 controls 
 
g
 
42
 
-secretase activity in pre-Golgi com-
partments. We discuss models that reconcile this con-
clusion with the effects of PS1 deﬁciency on the genera-
tion of 
 
b
 
A4(1-40) peptide in the late biosynthetic and 
endocytic pathways.
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 molecular cascades causing the complex neuro-
degenerative process of Alzheimer’s disease (AD)
 
1
 
are far from resolved. The pathological hallmarks,
i.e., senile plaques and tangles, of sporadic and familial
AD (FAD) are nevertheless similar, suggesting a common
pathogenic pathway. This allows us to approach the com-
plicated problem of the pathogenesis of the sporadic form
by the study of the genes and gene products involved in
FAD. Most of the familial forms of AD are caused by mis-
sense mutations in the genes coding for presenilin 1 (PS1)
and 2. The PS1/2 genes encode proteins of 467 and 448
amino acids, respectively, and show an overall amino acid
similarity of 67% (Levy-Lahad et al., 1995; Rogaev et
al., 1995; Sherrington et al., 1995). Their homology with
a series of related 
 
Caenorhabditis elegans
 
 proteins indi-
cates a conserved, albeit incompletely understood, func-
tion throughout evolution (Levitan and Greenwald, 1995;
Baumeister and Haass, 1998). Hydropathy plots suggest
up to 10 hydrophobic regions, of which most probably only
8 actually traverse the membrane (Li and Greenwald,
1996, 1998). Both the amino and carboxy termini as well as
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the large loop domain between hydrophobic regions 6 and
8 are orientated to the cytoplasm (Doan et al., 1996; De
Strooper et al., 1997; Lehmann et al., 1997; Li and Green-
wald, 1998). 
Although PS is synthesized as a full-length protein of
 
z
 
45 kD, it undergoes proteolytic cleavage within its hy-
drophilic loop domain, resulting in the generation of stable
amino-terminal (PS1-NTF) and carboxyl-terminal frag-
ments (PS1-CTF) in a 1:1 stoichiometry (Mercken et al.,
1996; Thinakaran et al., 1996; Capell et al., 1998). Except
for the G209V PS1 mutation (Levey et al., 1997), all mis-
sense mutations studied to date do not influence endopro-
teolysis significantly (Thinakaran and Sisodia, 1998). The
deletion mutant PS1
 
D
 
exon 9, in which exon 9 encoding the
cleavage site is deleted, prevents endoproteolysis and also
causes FAD, indicating that the clipping by itself is not a
prerequisite to develop the disease (Thinakaran et al.,
1996). At least one common effect of the clinical muta-
tions is an increased secretion of the highly amyloidogenic
 
b
 
A4(1-42) peptide as compared with the 
 
b
 
A4(1-40) pep-
tide. This effect has been demonstrated in cells derived
from affected individuals (Scheuner et al., 1996) as well as
in transfected cells and brains of transgenic mice (Borchelt
et al., 1996; Duff et al., 1996; Citron et al., 1997). The amy-
loid peptides are derived from the larger amyloid precur-
sor protein (APP) through consecutive clipping by two,
hitherto unknown, proteinases called 
 
b
 
- and 
 
g
 
-secretase.
A third enzyme, 
 
a
 
-secretase, cleaves the protein in the
amyloid region, precluding the formation of these amyloid
peptides (Haass and Selkoe, 1993). PS1 is directly involved
in 
 
g
 
-secretase processing of APP, as was demonstrated us-
ing knockout models. Targeted deletion of the PS1 gene
resulted in a greatly diminished production of 
 
b
 
A4(1-42)
as well as (1-40) peptides. As 
 
b
 
- (and 
 
a
 
-) clipping was vir-
tually normal in neurons derived from those animals, the
effect on APP processing is confined to 
 
g
 
-secretase activi-
ties (De Strooper et al., 1998). This observation was re-
cently considerably extended by the demonstration that
site-directed mutagenesis of either one of two aspartic res-
idues in the transmembrane domain 6 or 7, respectively, of
PS1 results in a dominant negative form of the protein
(Brockhaus et al., 1998; Steiner et al., 1999; Wolfe et al.,
1999). In cells overexpressing these mutant forms, a simi-
lar inhibition of 
 
g
 
-secretase processing is observed as in
the PS1-deficient cells (Wolfe et al., 1999). These results
are compatible with a catalytic role of presenilin. How-
ever, it remains difficult to explain how presenilin, which is
predominantly located in the early compartments of the
biosynthetic pathways, can influence the processing of
APP, which is thought to occur mainly in the late compart-
ments of this pathway, at the cell surface, and endosomes
(Sambamurti et al., 1992; Sisodia, 1992; De Strooper et al.,
1993; Koo and Squazzo, 1994; Haass et al., 1995; Selkoe,
1998).
The important issue raised by all these observations is
how presenilins can affect 
 
g
 
-secretase processing. Indeed,
from a cell biological point of view at least three possibili-
ties present themselves: (1) PS1 is indeed more widely dis-
tributed than believed until now and is located beyond the
Golgi apparatus; (2) APP–carboxy-terminal stubs are redi-
rected to the ER after their generation in the Golgi appa-
ratus in trafficking vesicles and at the cell surface; or (3)
 
PS1 affects 
 
g
 
-secretase and APP sorting to a common sub-
cellular compartment or microenvironment, affecting 
 
g
 
-sec-
retase processing of APP indirectly. To address this
problem, we have reinvestigated the subcellular localiza-
tion of the presenilins and the APP carboxy-terminal stubs
using advanced cell fractionation and confocal microscopy
and a panel of well-characterized subcellular marker pro-
teins. In addition, a series of APP sorting mutants was
used to delineate functionally the subcellular compart-
ment(s) where PS1 exerts its activity. We focused our
study on (transgenic) mouse brain and primary cultures of
hippocampal neurons, thereby avoiding possible artifacts
that could arise from overexpression of presenilins. In-
deed, in transiently or stable transfected cell lines, overex-
pressed PS1 exists in the ER and Golgi compartments
mainly as an uncleaved holoprotein, in contrast to the nor-
mal in vivo situation where PS1 is present as cleaved frag-
ments (Kovacs et al., 1996; Thinakaran et al., 1996, 1997;
De Strooper et al., 1997). It is far from clear whether this
overexpressed full-length protein remains biological func-
tional and whether it remains located in its physiologically
relevant compartment (Kovacs et al., 1996; Thinakaran et
al., 1996; De Strooper et al., 1997; Johnston et al., 1998). In
contrast, transgenic mice expressing PS1 do not accumu-
late full-length protein and display physiological relevant
levels of the cleaved fragments (Borchelt et al., 1996; Thi-
nakaran et al., 1996; Levesque et al., 1999). In this study,
brains and neurons derived from mice expressing endoge-
nous levels of mouse PS1, human wild-type PS1, PS1
 
M146L
 
or PS1
 
L286V
 
 were used. The Semliki Forest virus (SFV)
expression system allowed expression of APP as docu-
mented before (Liljestrom and Garoff, 1991; De Strooper
et al., 1995; Simons et al., 1996; Tienari et al., 1996b). We
paid particular attention to the effects of the PS mutations
on the formation of APP intermediate metabolites, such as
the 
 
a
 
- and 
 
b
 
-cleaved stubs, since this aspect of APP me-
tabolism has been somewhat neglected in previous studies.
In addition, we addressed the question of the combined ef-
fects of PS1 and the APP London mutation on APP pro-
cessing. Finally, three sorting mutants of APP were ana-
lyzed: one mainly processed in the early secretory pathway
(APP/KK), one in the late secretory pathway (APP-
 
D
 
CT),
and, finally, one targeted to the endosomal recycling com-
partment (APP/LDLR).
 
Materials and Methods
 
Viral Constructs
 
The cDNAs coding for human APP695, the London mutant, and human
APP695
 
D
 
CT, lacking the region encoding the carboxy-terminal cytoplas-
mic tail of APP, were cloned blunt end in the SmaI site of pSFV-1 as de-
scribed previously (Simons et al., 1996; Tienari et al., 1996b). APP695/KK
was generated by exchanging the two amino acids at position 3 and 4 of
APP695 to two lysines by site-directed mutagenesis (Chyung et al., 1997;
Peraus et al., 1997). The chimera APP695/LDLR was constructed by ex-
changing the carboxy-terminal cytoplasmic domain of APP with that of
the LDL receptor (cDNA provided by Walter Hunziker). In all sorting
mutants, an amino-terminal c-myc epitope (EQKLISEEDL) was inserted
into the KpnI site of the 5
 
9
 
-terminus of APP695 (Simons et al., 1995). All
cDNAs were verified by sequencing.
pSFV1/APP constructs were linearized with SpeI, and run-off tran-
scription using SP6 polymerase was performed to produce mRNA. The
transcribed mix of APP and pSFV-helper were cotransfected into BHK
cells by electroporation to yield recombinant SFV (Olkkonen et al., 1993). 
Annaert et al. 
 
Presenilin 1 Localization Versus APP Processing
 
279
 
BHK cells were grown in DME/F-12 supplemented with 5% FCS, 2 mM
 
L
 
-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. 24 h after
transfection, the culture supernatant containing infective recombinant
SFV was collected. Aliquots were snap-frozen in liquid nitrogen and
stored at –70
 
8
 
C until use.
 
Transgenic Animals and Neuronal Cell Culture
 
Transgenic FVB
 
3
 
C57 black mice expressing wild-type human PS1 or the
clinical mutants Met146Leu (PS1
 
M146L
 
) or Leu286Val (PS1
 
L286V
 
) under the
control of the prion promoter were used (Citron et al., 1997). The trans-
gene proteins were efficiently cleaved and their subcellular localization in
hippocampal neurons at different developmental stages was virtually in-
distinguishable from PS1 wild-type (Levesque et al., 1999).
Heterozygous transgenic mice were crossed with wild-type FVB mice,
and pregnant females were killed 17–18 d postcoitum. Hippocampal neu-
ron cultures were prepared from E17–E18-d-old fetal mice according to
Goslin and Banker (1991). Single cell suspensions obtained from the hip-
pocampi of individual embryos were plated on poly-
 
L
 
-lysine–coated plas-
tic dishes (Nunc) or on poly-
 
L
 
-lysine–coated coverslips in minimal essen-
tial medium (MEM) supplemented with 10% horse serum. After 3–4 h,
culture medium was replaced by serum-free neurobasal medium with B27
supplement (GIBCO BRL). Cytosine arabinoside (5 
 
m
 
M) was added 24 h
after plating to prevent nonneuronal (glial) cell proliferation. Hippocam-
pal neurons on plastic dishes were used at day 3 after plating. Hippocam-
pal neurons on coverslips were maintained in culture for 14–16 d in the
presence of a glial feeder layer to allow for full differentiation and polar-
ization.
 
Cell Fractionation
 
Brain cortices of 1-wk-old control and transgenic PS1 wild-type mice were
used as starting material. Since the transgene is under the control of the
prion promoter, the human PS1 is mainly expressed in neurons. Analysis
of the subcellular fractions obtained with this brain material using a hu-
man-specific antibody, therefore, reflects the distribution of PS1 in neu-
rons in vivo. This allowed us to directly compare the fractionation data
with the findings obtained in the cultured hippocampal neurons. The
preparation of nuclei and nuclear envelopes was based on the method de-
scribed by Otto et al. (1992) except that RNase 1 and PMSF were added
before centrifugation of the nuclear envelopes.
For the isolation of the intermediate compartment (IC) fractions, the
protocol of Schweizer et al. (1991) was used with modifications (Annaert
et al., 1997). Gradient fractions were collected using a Büchler Auto-
Densi Flow apparatus. Sucrose concentrations were calculated from the
refractive index (Refractometer RF 490; Euromex) by linear regression.
Highly purified intact lysosomes were prepared according to Maguire and
Luzio (1985).
The protein content of each fraction was measured spectrophotometri-
cally using a protein assay (Bio-Rad Laboratories) according to the manu-
facturer’s instructions. Unless stated otherwise, equal amounts of protein
(30 mg) were dissolved in Laemmli sample buffer, incubated for 10 min at
room temperature, and resolved on 13% polyacrylamide gels (Mini-Pro-
tean II; Bio-Rad Laboratories). After SDS-PAGE and transfer of the pro-
teins to nitrocellulose (Laemmli, 1970; Towbin et al., 1979), blots were
blocked in TBS containing 5% lowfat milk and 0.1% Tween 20 and incu-
bated overnight (4
 
8
 
C) with the appropriate primary antibodies. Detection
was done with HRP-conjugated secondary antibodies (Bio-Rad Laborato-
ries) followed by enhanced chemiluminescence (ECL; Amersham).
 
Indirect Immunofluorescence Microscopy
 
12-d-old hippocampal neurons were fixed in 4% paraformaldehyde and
4% sucrose in 120 mM sodium phosphate buffer, pH 7.3, for 30 min at
room temperature. Fixed neurons were rinsed twice in Dulbecco’s PBS
and transferred to ice-cold methanol (
 
2
 
20
 
8
 
C, for 4 min) followed by ice-
cold acetone (
 
2
 
20
 
8
 
C, for 2 min). Coverslips were transferred to a humid
chamber, washed three times with PBS, and blocked for 1 h at room tem-
perature or overnight at 4
 
8
 
C (blocking solution: PBS containing 2% BSA,
2% FCS, 0.2% fish gelatin, and 4% donkey serum). Neurons were subse-
quently incubated with primary antibodies in blocking solution (for 2 h at
room temperature). After four washes with PBS, secondary antibodies
were applied (for 2 h at room temperature). CY2- and CY3- or Lissamine
rhodamine-conjugated donkey anti–mouse and donkey anti–rabbit sec-
ondary antibodies (Jackson ImmunoResearch Laboratories) were used
for detection. Coverslips were washed three times with PBS, once in dis-
 
tilled water, and finally mounted in Mowiol (Calbiochem-Novabiochem).
Specimens were viewed through a Nikon Diaphot 300 (PlanApo 60/1.40
oil) connected to the MRC1024 confocal microscope (Bio-Rad Labora-
tories). Images were captured by LaserSharp (version 2.0) on a Com-
paq Prosignia 300 workstation and finally processed using Adobe Photo-
shop 5.0.
 
Antibodies
 
The following antibodies were used to detect PS1 (De Strooper et al.,
1997): polyclonal antibody B17.2 recognizes both human and mouse PS1-
CTF (peptide–antigen residues 300–315, EGDPEAQRRVSKNSKY of
the human PS1 sequence); and mAb 5.2 is specific for the human CTF-
PS1 (peptide–antigen residues 307–331, RRVSKNSKYNAESTERE-
SQDTVAEN). Polyclonal antibody B14.5 detects the human PS1-NTF
(peptide–antigen residues 30–44, NDNRERQEHNDRRSL); B19.2 and
B32.1 are directed against the murine PS1-NTF (peptide–antigen residues
32–46, SQERQQQHGRQRLDN) and PS1-CTF (peptide–antigen resi-
dues 310–330, PKNPKYNTQRAERETQDSGSG), respectively. All
polyclonal antibodies were affinity-purified against the peptide immobi-
lized on NHS-activated Sepharose 4b (Pharmacia) according to the manu-
facturer’s instructions. PS1 knockout brain tissue was used to confirm the
specificity of the PS1 affinity-purified polyclonal antibodies.
HoloAPP, 
 
a
 
- and/or 
 
b
 
-cleaved carboxy-terminal fragments of APP and
amyloid peptides were immunoprecipitated from cell extracts and media
using polyclonal antibodies raised against the 20 carboxy-terminal amino
acids of APP (B10/4 and B11/8) or against the synthetic human 1-40 
 
b
 
A4
peptide (B7/7) (De Strooper et al., 1995).
mAbs against lamin B1, a marker for nuclear envelopes, or against p58/
Golgi, a marker for Golgi membranes, were obtained from Zymed or
Sigma Chemical Co., respectively. mAbs to the transferrin receptor or to
synaptobrevin II (clone 69.1) were provided by Ian Trowbridge (Salk In-
stitute, San Diego, CA), and Reinhard Jahn (MPI-Biophysical Chemistry,
Göttingen, Germany), respectively. Monoclonal anti–c-myc antibody
(clone 9E10; Evan et al., 1985) was used for the detection of the carboxy-
terminal–inserted c-myc epitope.
Polyclonal antibodies to rSEC61
 
a
 
p, calnexin, BAP31, p58/ERGIC-53,
GM130, SEC23p, and TGN38 were provided by Enno Hartmann (Georg-
August Universität, Göttingen), Ari Helenius (Yale University, New Ha-
ven, CT), Michael Reth (MPI-Immunologie, Freibourg, Germany),
Jaakko Saraste (University of Bergen, Norway), Graham Warren (Yale
University, New Haven, CT), Jean-Pierre Paccaud, and George Banting
(Bristol, UK), respectively.
 
Viral Infection and Metabolic Labeling
 
Recombinant SFV was diluted 10-fold in conditioned culture medium and
added to the cells (1 ml/dish). Cultures were incubated for 1 h at 37
 
8
 
C to
allow entry of the virus, followed by incubation in conditioned medium in
the absence of virus (for 2 h). Metabolic labeling was performed using me-
thionine-free N2 medium containing 100 
 
m
 
Ci [
 
35
 
S]methionine/ml (NEN).
After 4 h, the conditioned medium was collected and the neuronal cell
layer was washed once in PBS, and then scraped in extraction buffer (20
mM Tris-HCl, pH 7.4, 150 mM NaCl containing 1% Triton X-100, 1% so-
dium deoxycholate, 0.1% SDS). Both the media and cell extracts were
centrifuged (14,000 rpm for 10 min) to remove detached cells and aggre-
gates. Polyclonal antibody B11/8 (1/500) was added to cell extracts and
B7/7 (1/100) to the media, together with protein G–Sepharose (Pharma-
cia) and incubated overnight (at 4
 
8
 
C). The immunoprecipitates were
washed five times in extraction buffer and once in TBS. To check the gly-
cosylation status of APPwt and the APP/KK mutant (see below), the
washed precipitate was treated overnight with endoH (20 mU; Boeh-
ringer) in phosphate buffer (at 37
 
8
 
C).
Immunoprecipitated proteins were solubilized with Tricine-SDS sam-
ple buffer (450 mM Tris-HCl, pH 8.45, 12% glycerol, 4% SDS, 0.0025%
Coomassie blue G, and 0.0025% phenol red). Samples were boiled (for 5
min) and electrophoresed on 10–20% Tris-Tricine gels (Novex). Radiola-
beled bands were detected by a PhosphorImager (Molecular Dynamics,
Inc.) and analyzed (ImageQuaNT 4.1). Levels of 
 
a
 
- and 
 
b
 
-cleaved car-
boxy-terminal stubs and secreted total 
 
b
 
A4 were normalized to the level
of expression of APP holoprotein precipitated from the cell extracts.
Sandwich ELISA assays to measure 
 
b
 
A4(1-40) and 
 
b
 
A4(1-42) used the
combination of antibodies G2-10/W02 and G2-11/W02, respectively
(Hartmann et al., 1997; Zhang et al., 1999). Nunc MaxiSorb immunoassay
plates were coated overnight at 4
 
8
 
C with 0.4 mg/well G2-10 in 100 mM
NaHCO
 
3
 
, pH 9.5, or with 1 mg/well G2-11 in 100 mM Tris-HCl, pH 7.4. 
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Subsequently, the antibody solution was removed and the wells were incu-
bated overnight at 4
 
8
 
C with 5% BSA in TBS. Wells were washed with
TBS plus 0.05% Tween 20 (TTBS) and were stored at 4
 
8
 
C (maximum 6
mo). Conditioned media were diluted with 10% BSA to yield a final con-
centration of 2% BSA and 100 ml of diluted media was added to each well
along with 40 ng/well biotinylated W02. Biotinylation of W02 was per-
formed with the EZ-Link TM Sulfo-NHS-LC biotinylation kit (Pierce
Chemical Co.) according to the manufacturer’s instructions. The plate was
incubated at 4
 
8
 
C with gentle shaking for 12 h (for 
 
b
 
A4(1-40) measure-
ments) or for 24 h (for 
 
b
 
A4(1-42) measurements). Plates were washed five
times with TTBS. 100 ml of 0.5 mg/ml HRP-conjugated NeutrAvidin
(Pierce Chemical Co.) was added to each well and plates were further in-
cubated at room temperature for 1 h. The color reaction was performed
with the TMB-H
 
2
 
O
 
2 
 
system (Kirkegaard & Perry Laboratories, Inc.) ac-
cording to the manufacturer’s instructions and absorption at 450 nm was
measured. For the assessment of intracellular 
 
b
 
A4, the cells of one 60-mm
culture dish were solubilized with 450 ml buffer containing 20 mM Tris-
HCl, pH 7, 2 mM EDTA, 0.2% SDS, 1% Triton X-100, 1% NP-40, and
protease inhibitors (0.7 mg/ml pepstatin A, 23 mg/ml PMSF, and 11 mg/ml
TPCK). 80 ml of the cell lysates was used for every measurement. The
sensitivity of the assays is 
 
z
 
50–100 pg/ml and values ranged between 60–
800 pg/ml for intracellular 
 
b
 
A4 and 100–3,500 pg/ml for secreted 
 
b
 
4A.
This large variation is mainly a consequence of variations in the number of
cells per dish.
 
Results
 
Mouse brain and hippocampal neurons derived from wild-
type mouse brain were used to localize endogenously ex-
pressed PS1 using subcellular fractionation and confocal
immunofluorescence microscopy. In addition, transgenic
mice expressing human PS1 under the control of the prion
promoter, which drives expression of the transgene in neu-
rons, were used for confocal microscopy and to obtain
fractionation data on the distribution of PS1 in neurons in
situ.
Because of their relatively high buoyant density, nuclei
can be easily purified by differential centrifugation in high
sucrose media. As is clear from Fig. 1, only a little PS1
staining is observed in purified nuclei, which contain
mainly histones in the protein fraction (not shown). How-
ever, additional DNA digestion combined with ultracen-
trifugation yields a fraction of highly purified nuclear
envelopes, as demonstrated by the abundant lamin B1
immunoreactivity (Fig. 1 a, NE). Interestingly, this final
purification step results in a strong enrichment for PS1-
CTF and -NTF immunoreactive bands (Fig. 1 a), indicat-
ing that the little amount of PS1 present in the nuclei is al-
most exclusively associated with the nuclear envelope. It
should be noticed that this fraction also stains with cal-
nexin antibodies, in agreement with the continuity be-
tween nuclear envelope and RER. Remarkably, in this
nuclear envelope fraction, a prominent immunoreactive
band representing full-length PS1 is detected with both
NTF- and CTF-specific antibodies (Fig. 1 a and not
shown) (see below). The presence of presenilin in the nu-
clear envelope was confirmed in fixed polarized hippo-
campal neurons using confocal microscopy. PS1 immu-
noreactivity colocalized with lamin B1 in confocal sections
through the middle of the nucleus (Fig. 1 b, arrows). To-
gether, these results indicate that PS1 fragments and PS1
holoprotein are present in the nuclear envelope.
Next, the distribution of PS1 was investigated in pre-
Golgi compartments of hippocampal neurons derived
from human PS1wt transgenic mice (Fig. 2). rSEC61
 
a
 
p is
an essential component of the mammalian ER protein
translocation complex and is tightly associated with mem-
brane-bound ribosomes in RER (Gorlich et al., 1992). PS1
immunoreactivity was found to codistribute only partially
with the reticular staining pattern observed for rSEC61
 
a
 
p
(Fig. 2, a–c, arrowheads). In contrast, a considerable frac-
tion of PS1 staining, especially obvious in the perinuclear
region, did not localize with rSEC61
 
a
 
p (Fig. 2, a–c, arrow).
Antibodies to calnexin (Fig. 2, d–f) and BAP31 (Fig. 2, g–i),
two proteins that are abundantly distributed throughout
the ER, displayed a reticular staining that overlapped very
well with most of the immunolabeling for PS1-CTF. How-
ever, it should be noticed that several distinct PS1-positive
spots did not colocalize with calnexin immunoreactivity.
Transport from the ER to the IC and Golgi apparatus oc-
curs in specific subdomains of the ER where transported
Figure 1. (a) Purification of nu-
clei (N) and nuclear envelopes
(NE) from cortices of 5–7-d-old
mice by differential centrifuga-
tion (Otto et al., 1992). Brains
were homogenized in 0.32 M
sucrose containing 1 mM MgCl2
and 20 mM Hepes, pH 7.4. The
total homogenate (TH) was
centrifuged (at 200 gav for 20
min), the resulting pellet (P1)
resuspended to a final concen-
tration of 1.8 M sucrose and
centrifuged again (at 67,000 gav
for 1 h). The pellet P2 was re-
suspended to a final concentra-
tion of 2.15 M sucrose, layered
on a 2.2 M sucrose cushion and
centrifuged (at 67,000 gav for 1 h).
The pellet of purified nuclei (N) was, after DNAse digestion,
centrifuged (at 9,500 gav for 20 min) to obtain nuclear envelopes
(NE). Equal amounts of protein of each intermediate step was
analyzed by SDS-PAGE and Western blotting. The final fraction
(NE), which is highly enriched for lamin B1, also contains low
amounts of PS1 fragments and full-length PS1. (b) Double immu-
nofluorescent staining of fully polarized hippocampal neurons
(16 d of culture) derived from nontransgenic embryos for PS1
(red) and lamin B1 (green). A merged picture shows consider-
able overlap of both stainings (yellow). Anti-PS1 pAb B17.2 was
detected with CY3 anti–rabbit antibodies, whereas anti–lamin B1
mAb was detected with CY2-conjugated anti–mouse antibodies.
Note that the focal plane is through the middle of the nucleus.
The bulk of PS1 immunoreactive staining is localized close to the
bottom of the cell and in the dendritic arbor (see next figure). Ar-
rowheads point to rims of the nuclear envelope that costains for
PS1-CTF (see also yellow color in overlay). Bar, 20 mm. 
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proteins are concentrated in budding transport vesicles
coated by COPII coat proteins (Barlowe et al., 1994).
SEC23p is one of the cytosolic components of this COPII
coat complex. As shown in Fig. 2, j–l, this COPII protein
displayed an overall colocalization with PS1-CTF (Fig. 2 l,
inset, yellow). At a higher magnification, all PS1-CTF–
positive patches were also immunolabeled for SEC23p
(see detailed area in Fig. 2, j–l). These export sites are of-
Figure 2. Double immuno-
fluorescent staining of fully
polarized hippocampal neu-
rons derived from PS1wt
transgenic embryos for PS1
(red in all pictures) and
rSEC61ap (a–c), calnexin (d–
f), BAP31 (g–i), SEC23 (j–l),
and ERGIC-53/p58 (m–o).
Fields c, f, i, l, and o represent
color overlays. mAb 5.2 was
used to label human PS1wt
and detection was done with
CY3 anti-mouse secondary
antibodies. All other marker
proteins were counterstained
using CY2-conjugated anti–
rabbit secondary antibodies.
Notice the relative weak colo-
calization of PS1 with the
RER marker rSEC61ap (a–c,
arrowheads) mainly in the
perinuclear region (a-c, ar-
row). PS1 colocalizes much
better with other ER marker
proteins such as calnexin
(d–f), BAP31 (g–i), and
SEC23 (j–l), or with ERGIC-
53/p58, a resident protein of
the IC. The pictures in (j–o)
give a detailed area of the
fully polarized neuron as over-
viewed in the insets. Bars:
(a-i) 20 mm; (j-o) 10 mm. 
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ten found juxtaposed to vesiculotubular clusters (VTCs)
of the IC (Bannykh and Balch, 1998). Indeed, immunola-
beling of ERGIC-53/p58, so far the best characterized IC
resident protein (Schweizer et al., 1991; Klumperman et
al., 1998), showed a close colocalization with PS1-CTF
(Fig. 2, m–o). Therefore, these results indicate an abun-
dant localization of presenilin in the ER.
Especially the close overlap with SEC23p and ERGIC-
53 prompted us to further document the interesting local-
ization of PS1 in the transit zone between ER and Golgi.
We applied a cell fractionation scheme described by
Schweizer et al. (1991) that allows one to obtain highly en-
riched fractions of the IC in VERO cells. This method
starts with a Percoll gradient centrifugation step, resulting
in a rough separation of RER and Golgi membranes. When
applied on the postnuclear fraction of mouse brain, most
of the PS1 immunoreactivity was detected in two peaks
(Fig. 3 a). One small peak (15.1 
 
6 
 
0.5% of total PS1-CTF
or 19.4 
 
6 
 
3.3%, 
 
n 
 
5
 
 3, of total PS1–NTF immunoreactiv-
ity, respectively) was associated with the bottom fractions
of the gradient coinciding with the distribution of the RER
marker protein rSEC61
 
a
 
p (Fig. 2 a), confirming that a rel-
ative low amount of PS1 is associated with the RER com-
partment. A second, major peak (pool II: 42.7 
 
6 
 
2.4% for
PS1-CTF and 48.1 
 
6 
 
0.5%, 
 
n 5 3, for PS1–NTF) was lo-
cated in the low density region coinciding with the density
of Golgi membranes (Fig. 3 a and Schweizer et al., 1991).
Typically, IC membranes equilibrate as a broad peak in
the midportion of this self-formed gradient. Fractions
5–14, containing 61.6 6 7.3% (n 5 3) of the total ERGIC-
Figure 3. Analysis of PS1 in
enriched fractions of the IC
isolated from cortices of 5–7-d-
old mice (adapted from
Schweizer et al., 1991). (a)
A postnuclear supernatant
(PNS) was mixed with Percoll
to give a final density of 1.129
g/ml and centrifuged (at
37,000 gmax for 41 min).
Twenty-two fractions of 1.5
ml were collected and ana-
lyzed by SDS-PAGE and
Western blotting (equal
amount of fraction volume).
PS1 immunoreactivity was
distributed bimodally with
most of the immunoreactiv-
ity recovered in fractions 15–
19. (b) Fractions 5–14 were
pooled (Pool I), adjusted to
30% (wt/wt) Nycodenz, and
overlaid with 27% and 18.5%
(wt/wt) Nycodenz. After iso-
pycnic centrifugation (85,800
gmax for 20 h), three interfaces
were collected (F1, F2, and
F3). The 18.5–27% interface
F3 is highly enriched in
marker proteins for the inter-
mediate compartment (IC),
such as p58/ERGIC-53. Com-
parable enrichments were
found for both PS1-NTF and
-CTF. Equal amounts of pro-
tein were analyzed by SDS-
PAGE and Western blotting.
For PS1-NTF, an additional
long exposure of the same
blot is shown to reveal the
full-length PS1. Notice that
the F3 fraction is still contam-
inated with membranes derived from the RER as demonstrated by two specific marker proteins, rSEC61ap and TRAPa. (c) The inter-
face fraction F3 was diluted twofold with buffer C (Schweizer et al., 1991) and loaded on a continuous sucrose gradient (0.8–1.6 M su-
crose in buffer C). After isopycnic gradient centrifugation (SW41 rotor, at 250,000 gmax for 4 h), 12 fractions were collected from the top
and analyzed by Western blotting. Calnexin, ERGIC-53/p58 and PS1 fragments all display a bimodal distribution, whereas TRAPa and
rSEC61ap are only distributed in the second half of the sucrose gradient. The bottom panel shows the distribution of the different
marker proteins expressed per milligram of protein in each fraction (arbitrary units/mg protein). It should be noted that at low sucrose
densities (first half of the gradient), both PS1 fragments clearly coenrich with the first pool of ERGIC-53/p58–positive membranes,
whereas no clear enrichment is observed for calnexin. The data represent one out of two independent experiments.Annaert et al. Presenilin 1 Localization Versus APP Processing 283
53/p58 immunoreactivity contained 25.1 6 2.1% of PS1-
CTF and 17.9 6 1.5% of PS1-NTF (n 5 3). This fraction
was pooled (Fig. 3 a, Pool I) and further purified and con-
centrated by an additional centrifugation step in a discon-
tinuous Nycodenz gradient (Fig. 3 b). Three interfaces, F1,
F2, and F3, are recovered. The interface F3 at 18.5–27%
Nycodenz is highly enriched in IC membranes, as demon-
strated by the strong immunoreactivity for p58/ERGIC-53
(Fig. 3 b). Both PS1-NTF and -CTF coenrich to a similar
extent in this final F3 fraction. Unfortunately, and in con-
trast to the original method (Schweizer et al., 1991), immu-
noblotting for rSEC61ap and TRAPa, a protein associ-
ated with the translocon site (Hartmann et al., 1993),
revealed contamination of F3 with RER membranes (Fig. 3
b). This discrepancy is probably a consequence of the dif-
ference in starting material, i.e., VERO cells versus mouse
brain used here. Therefore, we purified the F3 fraction in
an additional continuous sucrose gradient (0.8–1.6 M
sucrose). Whereas the marker proteins calnexin and
ERGIC-53/p58 displayed together with PS1 a bimodal dis-
tribution (Fig. 3 c), the rSEC61ap and TRAPa immunore-
activity was solely recovered in the high density region of
the gradient. Thus, the PS1 immunoreactivity in the low
density region (fractions 4 and 5) of the gradient cannot be
explained by contaminating RER membranes. Further-
more, we quantified all marker proteins by densitometric
scanning. When the results were expressed as density units
per milligram of protein (Fig. 3 c, bottom), it became ob-
vious that PS1 fragments specifically coenriched with
ERGIC-53/p58 rather than with calnexin, suggesting their
localization in the IC. Moreover, the enrichment factor
for ERGIC-53/p58 obtained in the low density peak frac-
tion was 35 compared with total homogenate, reaching a
similar degree of enrichment as originally described for
VERO cells (Schweizer et al., 1991).
From the initial Percoll gradient (Fig. 3 a), a major peak
of PS1 immunoreactivity (Pool II) can be observed corre-
sponding to less dense regions where Golgi-derived mem-
branes tend to equilibrate (Schweizer et al., 1991). To ana-
lyze whether this reflected an association of PS1 with
Golgi membranes, we further purified the pooled fractions
15–19 using discontinuous Nycodenz gradient centrifuga-
tion consisting of three layers of different Nycodenz con-
centrations. Most of the PS1 immunoreactivity was recov-
ered in the 14–21% interface (IF3) together with marker
proteins of the Golgi apparatus (such as GM130). This in-
terface IF3 was loaded on a continuous sucrose gradient
(0.3–1.7 M sucrose) and the distribution of PS1 was ana-
lyzed after ultracentrifugation (Fig. 4 A). Established
Golgi marker proteins such as GM130 (Fig. 4 A) and
b-cop (not shown) equilibrated at high sucrose densities in
fractions 4 and 5, whereas the bulk amount of PS1-CTF
and -NTF immunoreactivity was recovered at a lower
buoyant density with a peak in fractions 7 and 8. The strik-
ing similar distributions of the unglycosylated form of
TGN38 (Fig. 4 A, Mr 45,000) and RAP with the PS1-CTF
and -NTF indicate that the PS1 in this pool is mainly asso-
ciated with early cis-Golgi membranes. Indeed, unglycos-
ylated TGN38 is located in the early cis-Golgi, whereas
RAP is a molecular chaperone assisting membrane pro-
teins such as the LDL receptor in their passage through
the early secretory pathway between the ER and Golgi
(Bu and Schwartz, 1998). Since the IC resident protein
p58/ERGIC-53 did not codistribute with fractions 7 and 8,
these fractions may identify a membrane-bound interme-
diate between the IC and cis-Golgi. Mature (glycosylated)
TGN38, which is a marker for the TGN tubules, is mainly
found in the bottom fraction (Fig. 4 A, fraction 1). Since
this fraction is completely devoid of PS1 immunoreactiv-
ity, we can assume that PS1 does not reach the TGN in sig-
nificant amounts.
This observation was entirely corroborated by confocal
laser microscopy of control hippocampal neurons. Anti-
bodies against the peripherally associated 58-kD Golgi
protein (Fig. 4 B, p58/Golgi), detected Golgi staining re-
stricted to the cell body and proximal dendrites of neurons
(Fig. 4 B, a–c) in agreement with Krijnse-Locker et al.
(1995). At first glance (Fig. 4 B, c), a high degree of over-
lap with the immunostaining for PS1-CTF seemed to be
observed. However, when a more careful analysis was per-
formed at a higher magnification (Fig. 4 B, d–f), only a
limited overlap could be demonstrated (Fig. 4 B, d–f, as-
terisk and arrowhead). This becomes even more clear in
the vertical plane section of a proximal dendrite (Fig. 4 B,
g–i; the arrow in d–f indicates the site of the section). PS1-
CTF staining was concentrated in defined stacks often
capped by or juxtaposed to staining for p58/Golgi (Fig. 4
B, g–i, arrowheads). Both proteins colocalized only par-
tially in discrete areas. This is in line with the fractionation
data.
a- and b-secretase cleavage of APP occurs in the late
Golgi, in transport vesicles, at the cell surface, and in en-
docytic compartments (Selkoe, 1998), generating the a-
and  b-APP carboxy-terminal stubs associated with the
membranes. These stubs are the direct substrates for
g-secretase. Given the restricted distribution of PS1 in the
ER, IC, and early cis-Golgi compartments, the question
arises how the g-secretase cleavage of these APP stubs can
be controlled by PS1.
Therefore, we analyzed the distribution of endogenous
APP in the same fractions analyzed before for presenilin
immunoreactivity. As shown in Fig. 5 a, both the gradient
distributions of the APP holoprotein and the APP car-
boxy-terminal fragments were bimodal, which is similar to
what was found for PS1 (Fig. 3 a). The larger amounts are
found in the fractions of Pool II. Further purification re-
sulted in the concomitant enrichment for the APP car-
boxy-terminal fragments in the F3 interface (Fig. 5 b),
where PS1 is also recovered. Remarkably, this enrichment
was much less obvious for the APP holoprotein, suggest-
ing a selective accumulation of the carboxy-terminal APP
fragments in this fraction. Further analysis of the Pool II–
associated APP immunoreactivity revealed the enrich-
ment of the APP carboxy-terminal fragments in exactly
the same fractions of the sucrose gradient where PS1 frag-
ments (together with RAP) are recovered (compare Fig. 5
c with Fig. 4 A). Interestingly, therefore, the carboxy-ter-
minal fragments of APP are apparently at least partially
codistributing with PS1-NTF and -CTF in the same subcel-
lular membrane compartments (see Discussion). Given
the existing controversy whether or not PS1 can be found
in compartments beyond the ER/IC and cis-Golgi, we ex-
tended our study to some well-defined post-Golgi com-
partments such as lysosomes, endosomes, synaptic vesi-The Journal of Cell Biology, Volume 147, 1999 284
Figure 4. Analysis of PS1 immunoreactivity in the Golgi apparatus by cell fractionation (A) and confocal microscopy (B). (A) Fractions
15–19 of the Percoll gradient (see Fig. 3 a) were pooled (Pool II), adjusted to 25% (wt/wt) Nycodenz, and overlaid with 21, 14, and 10%
(wt/wt) Nycodenz. After isopycnic centrifugation (SW41 rotor; at 85,800 gmax for 20 h), three interfaces were collected (IF1, IF2, and
IF3, not shown). Interface IF3, containing most of the PS1 immunoreactivity (not shown) was diluted twofold with buffer C (Schweizer
et al., 1991) and further fractionated by continuous sucrose density gradient centrifugation (0.3–1.7 M sucrose, at 250,000 gmax for 2 h).
Fractions were collected from the bottom and an equal volume of each fraction was analyzed. The peak immunoreactivity for PS1-NTF
and -CTF was slightly shifted to less dense regions of the gradient, thereby codistributing with BAP31, RAP, and immature TGN38.Annaert et al. Presenilin 1 Localization Versus APP Processing 285
cles, the cell surface, and clathrin-coated vesicles. Both
PS1 fragments clearly purify away from mature and intact
lysosomes (Fig. 6, compare with the enrichment for cathe-
psin D), and were observed only after prolonged exposure
times. The weak immunoreactivity in the pure lysosomal
fractions is most likely a consequence of minor contamina-
tion of the isolated fraction.
We also investigated the possible colocalization of CTF-
PS1 with marker proteins of post-Golgi compartments
such as the transferrin receptor and synaptobrevin II in
hippocampal neurons of control, nontransgenic mice (Fig.
7). In fully polarized neurons, the transferrin receptor is
localized somatodendritically and, accordingly, numerous
transferrin receptor–positive punctae are noticed in the
dendritic arbor (Fig. 7, a–c, dendrites, and d–f, growth
cone). Virtually no overlap is observed for PS1-CTF and
transferrin receptor staining, indicating that PS1 is not
present in recycling endosomes. Synaptobrevin II is often
used as a marker for synaptic vesicles that cluster in spe-
cialized axonal regions of mature neurons referred to as
synaptic boutons. Again no immunostaining for PS1 could
be detected within these boutons (Fig. 7, g–l, with emphasis
on the detailed area in g–i), suggesting that no PS1 is asso-
ciated with the membranes of synaptic vesicles. Further
analysis of highly purified clathrin-coated vesicles from
nerve terminals, or double immunostaining with specific
cell surface marker such as ICAM-5, and surface biotinyla-
tion experiments (not shown) did not yield any conclusive
evidence that PS1 could be associated with clathrin-coated
vesicles or with the cell membrane. (data not shown). It is
clear that the amounts of presenilin present in the mem-
branous compartments beyond the ER–cis-Golgi in hip-
pocampal neurons are very limited and, in any event,
below the detection limits of our current available tech-
nology. In conclusion, the data obtained from both cell
fractionation and immunofluorescence studies on brain
and neurons, demonstrate the abundant association of
PS1 with the ER, IC, and to a lesser extent, the early cis-
Golgi.
This prompted us to further investigate the relationship
between APP processing and presenilin at a more func-
tional level. Therefore, we generated a series of APP traf-
ficking mutants that limit APP processing to specific sub-
cellular compartments. A dilysine motif was added to the
carboxy terminus of APP to retain APP/KK in pre-Golgi
compartments, thereby emphasizing the bA4(1-42) pro-
duction (Chyung et al., 1997). Reinternalization of cell sur-
face APP was blocked by deleting the cytoplasmic tail
Mature TGN38 immunoreactivity was mainly recovered in the bottom fraction of the gradient. GM130, a Golgi marker, is distributed in
the high density region of the gradient where no peak of PS1 immunoreactivity was observed. (B) PS1 does not distribute extensively
into the Golgi apparatus. Fully polarized neurons isolated from control, nontransgene embryos were double stained for PS1 (pAb
B17.2; red) and p58/Golgi (green). Detection was performed with CY3 anti-rabbit and CY2 anti-mouse secondary antibodies, respec-
tively. In contrast to PS1 labeling (b), Golgi staining (a) is restricted to the soma and proximal part of the dendrites as can be seen in the
overview of a neuron (a–c, arrow). (d–f) Enlarged area of the proximal dendrite in the same neuron stained for PS1 (red) and p58/Golgi
(green). The asterisk indicates regions in the cell body with a relative low level of colocalization. Arrowheads point to areas of codistri-
bution. (g–i) Section in the vertical plane of the neuron at the position in the proximal dendrite indicated by the arrow in (d–f). Only a
partial overlap is observed and in many cases, PS1 immunoreactivity is very closely juxtaposed to p58/Golgi staining (arrowheads in
g–i). c, f, and i are the merged signals. PS1 and Golgi stainings are mainly not overlapping. Bars, 10 mm.
Figure 5. Analysis of the distri-
bution of APP holoprotein and
carboxy-terminal fragments in
ER- and IC-enriched fractions
isolated from cortices of 5–7-d-old
mice using the same fraction-
ation protocol as described in
Fig. 3, a and b, and Fig. 4 (A).
(a) Distribution of APP after
Percoll gradient centrifugation
of a postnuclear fraction. Like
for PS1, both APP and APP
stubs display a bimodal distribu-
tion with the major amount of
immunoreactivity in fractions
15–20 of the gradient. (b) APP
carboxy-terminal fragments en-
rich in the interface F3. (c) APP
fragments could be further en-
riched after Nycodenz and su-
crose gradient centrifugation of
Pool II from the Percoll gradient
(a). The distribution of APP car-
boxy-terminal fragments is iden-
tical to that of PS1-NTF and
-CTF (Fig. 4 A).The Journal of Cell Biology, Volume 147, 1999 286
(APPDCT), limiting APP trafficking to the biosynthetic
pathway (Tienari et al., 1996b), and severely impairing
bA4 secretion (Perez et al., 1999). A chimerical APP/
LDLR was generated by replacing the cytoplasmic do-
main of APP by that of the LDL receptor. This mutation
increases the recycling of APP in the endosomal compart-
ments and promotes bA4(1-40) production (see below).
We also investigated the effects of the clinical APP/Lon-
don mutation in combination with the PS1 mutations, to
see whether these mutations operate additively or not.
The APP constructs were expressed in neurons using the
SFV expression system. Similar expression levels for all
constructs were obtained in hippocampal cultures, except
for APPDCT (Fig. 8, CELL). For comparisons between
the different experiments, the obtained phosphorimaging
results were normalized to the expression levels of APP
holoprotein in the cell extracts. Expression of APPDCT
led to decreased bA4 secretion concomitantly with the
production of a short cell-associated b-stub. In the case of
APP/KK infection, the decrease of secreted bA4 was even
more pronounced (also see below). The APP/KK mutant
is actively retrieved from the cis-Golgi to the ER as a con-
sequence of the dilysine motif. This was confirmed by its
complete endo-H glycosidase sensitivity (data not shown)
and its codistribution with calnexin (Fig. 9 b) and endoge-
nous PS1 (Fig. 9 c). The striking colocalization of endoge-
nous PS1 with virally expressed APP/KK (Fig. 9 c, inset)
should be noticed. As a control, SFV-APPwt is shown,
which confirms the axonal delivery of this protein (Fig. 9
a) (Simons et al., 1995; Yamazaki et al., 1995; Tienari et
al., 1996b). We analyzed systematically the metabolism of
the expressed APP mutants (Table I). Quantitative immu-
noprecipitation and phosphorimaging determined the to-
tal amounts of cell-associated a- and b-stubs and secreted
bA4. To standardize and to allow comparisons between
different experiments, we normalized all values to cell-
associated APP holoprotein. Similarly, normalization of
the numbers obtained in the ELISA experiments was per-
formed because of the relative large variations in the abso-
Figure 6. Purification of lysosomes from cortices of 5–7-d-old
mice. Highly purified lysosomes were obtained by a combination
of low speed centrifugation in 0.25 M KCl and velocity gradient
centrifugation in Percoll according to the method of Maguire and
Luzio (1985). The final lysosomal fraction (LYS) is clearly en-
riched in cathepsin D. Hardly any PS1-NTF or -CTF immunore-
activity was detected in this fraction.
Table I. Processing of APP in Hippocampal Neurons
¯Transgene a-stub/APPcell b-stub/APPcell Secreted bA4/APPcell Secreted 1-42/1-40 Intracell. 1-42/1-40
A. SFV-APP wild-type
Control 1.00 6 0.04 (17) 1.00 6 0.04 (17) 1.00 6 0.04 (18) 1.00 6 0.02 (17) 1.00 6 0.05 (17)
PS1wt 0.86 6 0.04 (14) 0.91 6 0.03 (12) 0.99 6 0.07 (15) 0.90 6 0.17 (4) 1.37 6 0.20 (5)
PS1L286V 1.02 6 0.13 (4) 0.84 6 0.08 (5) 0.89 6 0.08 (6) 1.30 6 0.10 (6)* 1.13 6 0.20 (6)
PS1M146L 1.08 6 0.06 (6) 1.05 6 0.08 (6) 1.27 6 0.13 (6)*‡ 1.95 6 0.13 (8)*‡ 0.98 6 0.11 (8)
B. SFV-APP London
Control 1.00 6 0.07 (13) 1.00 6 0.06 (13) 1.00 6 0.05 (13) 1.00 6 0.03 (10) 1.00 6 0.08 (11)
PS1wt 0.84 6 0.09 (11) 0.85 6 0.10 (11) 0.87 6 0.11 (11) 0.91 6 0.08 (5) 1.38 6 0.18 (3)
PS1L286V 0.64 6 0.09 (8)* 0.74 6 0.10 (8)* 1.09 6 0.07 (8) 1.38 6 0.07 (8)* 1.44 6 0.19 (8)
PS1M146L 0.58 6 0.08 (5)* 0.75 6 0.12 (5)* 1.02 6 0.34 (5) 2.97 6 0.65 (3)*‡ 1.14 6 0.04 (3)
C. SFV-APPDCT
Control n.d. 1.00 6 0.08 (9) 1.00 6 0.06 (9) 1.00 6 0.05 (17) 1.00 6 0.05 (17)
PS1wt n.d. 1.68 6 0.16 (3)* 1.22 6 0.07 (3)* 1.13 6 0.07 (3) 1.23 6 0.12 (3)
PS1L286V n.d. 1.04 6 0.14 (3) 0.93 6 0.12 (3) 1.24 6 0.04 (7)* 1.11 6 0.12 (7)
PS1M146L n.d. 0.89 6 0.06 (6) 1.16 6 0.11 (6) 1.55 6 0.11 (7)*‡ 1.05 6 0.13 (7)
D. SFV-APP/KK
Control 1.00 6 0.03 (7) 1.00 6 0.04 (7) 1.00 6 0.10 (7) 1.00 6 0.11 (9) 1.00 6 0.11 (9)
PS1wt 0.96 6 0.06 (7) 0.88 6 0.05 (7)* 0.92 6 0.10 (3) n.d. n.d.
PS1L286V 0.98 6 0.04 (3) 0.83 6 0.04 (3)* 1.03 6 0.04 (3) 1.09 6 0.08 (3) 0.58 6 0.06 (3)*
PS1M146L 1.01 6 0.04 (4) 0.92 6 0.03 (4) 1.90 6 0.29 (4)*‡ 2.83 6 0.57 (6)*‡ 1.07 6 0.07 (6)‡
Analysis of the processing of APP in hippocampal neurons with Semliki Forest virus expressing human APP wild-type (A), APP-London mutation (B), carboxy-terminal–trun-
cated mice APP (APPDCT, C) or APP/KK (D). Primary neuronal cultures are derived from transgenic mice expressing human PS1 wild-type (PS1wt) or a clinical mutation of PS1
(PS1L286V and PS1M146L).
The data represent the ratios of the a- and b-secretase cleaved carboxy-terminal fragments and the total secreted bA4 amyloid peptides to the APP-holoprotein in the cell extracts,
as well as the ratios of secreted and intracellular bA4 1-42/bA4 1-40 amyloid peptides. All ratios are normalized to the ratios found in control, nontransgenic cultures (control val-
ues in the first line of each table). The number between brackets denotes the number of cultures analyzed for each condition. Data are presented as mean 6 S.E.M. n.d.: not deter-
mined. For table A–D, numerical values in each column were further statistically analyzed by ANOVA and t test.
*Significantly different (P , 0.05) from control, nontransgenic cultures (first row in each table).
‡Significantly different (P , 0.05) from transgenic PS1L286V cultures (third row in each table).Annaert et al. Presenilin 1 Localization Versus APP Processing 287
lute amounts of peptide produced in separate independent
experiments. Therefore, only ratios of secreted and intra-
cellular  bA4(1-42)/(1-40) are given. Except for APP/
LDLR, all constructs were completely analyzed in the
three types of neuronal culture, i.e., expressing human PS1
wt or the clinical mutants PS1L286V or PS1M146L. The results
were compared with those obtained in cells derived from
control and nontransgenic littermate embryos. Table I
summarizes the data obtained for APPwt (A), the London
mutant (B), APPDCT (C), and APP/KK (D).
With respect to a- and b-cleaved carboxy-terminal frag-
ments, no significant differences were noticed related to
PS1 wild-type or clinical mutants except for the London
mutant. The clinical mutations in PS1 do not affect a- and
Figure 7. PS1 is not localized in recycling endosomes and synaptic vesicles of hippocampal neurons derived from control, nontransgene
embryos. (a–f) Within the somatodendritic area of 14-d-old hippocampal neurons, PS1 (pAb B17.2; red) is not colocalized with the
transferrin receptor (green). A detailed area of distal parts of the dendritic arbor (a–c) and a growth cone (d–f) are shown. (d–i) Double
immunofluorescent staining of hippocampal neurons for PS1 (pAb B17.2; red) and the synaptic vesicle marker synaptobrevin II (mAb
69.1, green). Axonal, presynaptic boutons are marked by synaptobrevin II immunoreactive punctae and are devoid of PS1 immunoreac-
tivity, most clearly seen in the enlarged area displaying an axon running parallel with a dendrite while making several synaptic contacts
(g–i). PS1 is distributed into the postsynaptic areas. PS1 was stained with CY3 anti-rabbit, the transferrin receptor and synaptobrevin II
with CY2 anti-mouse secondary antibodies. Bars, 10 mm.The Journal of Cell Biology, Volume 147, 1999 288
b-secretase activity, complementing the data obtained pre-
viously in PS1-deficient neurons (De Strooper et al., 1998).
However, in the case of the London mutant, levels of a-
and b-stubs were surprisingly decreased in the FAD mu-
tant PS1 neurons. This reflects probably the increased
turnover of both stubs by g-secretase cleavage, in ac-
cordance with the strong additive effects of the London-
and FAD-linked PS1 mutations (especially PS1M146L) on
g-secretase processing (see below).
To evaluate g-secretase activities, we measured the total
pool of secreted bA4 by immune precipitation as well as
the ratio of the individual peptides by ELISA. A modest
increase in the total amount of secreted bA4 was observed
for the PS1M146L mutant. This effect was not very dramatic
(except for the APP/KK, see below). In contrast, PS1 mu-
tations caused dramatic increases in the bA4(1-42) to
bA4(1-40) peptide ratio, and this effect was even more
pronounced when the effect of the mild overexpression of
PS1wt alone was directly compared with that of PS1 con-
taining clinical mutations. The PS1M146L mutation was
overall more effective than the PS1L286V mutation.
The London mutation on its own caused a threefold in-
crease (3.4460.43; n 5 6) in the ratio of secreted bA4(1-
42)/(1-40) versus APP wild-type in control neurons (not
shown). Interestingly, an additional rise in this ratio was
observed in combination with PS1 mutations (Table I B).
This rise ranged from 1.3860.07 (n 5 8) for the PS1L286V
mutation to 2.9760.65 (n 5 3) for the PS1M146L mutation.
When compared with APPwt expressed in wild-type neu-
rons, the total raise ranged up to 12.3 6 3.1 (n 5 3). The
increase appears to be solely due to an increased secretion
of the b4A(1-42) peptide and not a consequence of a de-
creased bA4(1-40) production, explaining the decrease in
a- and b-carboxy-terminal fragments as mentioned above.
APPDCT in control neurons yielded low levels of se-
creted bA4. However, the ratio between the two peptides
was slightly raised compared with SFV-APPwt (1.3060.14,
n 5 8, versus SFV-APPwt). This ratio increased even fur-
ther when this mutant was expressed in PS1M146L neurons
(Table I C). For APP/KK, the total secretion of bA4(1-40)
was also lowered dramatically to 5.061.6% (n 5 6) when
compared with APPwt (see also Fig. 8). The bA4(1-42) se-
cretion was not affected as strongly as the bA4(1-40) se-
cretion and only dropped to 18.064.7% (n 5 6) when
compared with APPwt. The introduction of the ER-
retrieving dilysine motif on its own, therefore, caused an
appreciable increase in the 42:40 ratio of the secreted pep-
tides to 3.9860.70 (n 5 6) times relative to APPwt. Upon
expression in PS1M146L neurons, an additional raise in this
ratio of 2.8360.57 (n 5 6, Table I D) was observed. The
increase could again solely be contributed to an increased
secretion of the bA4(1-42) peptide. Interestingly, only for
this construct, a sharp rise in total secreted bA4 was no-
ticed in PS1M146L neurons. It should be noticed that the
main peptide produced by APP/KK is bA4(1-42). This ob-
servation indicates that some of the presenilin mutations
do not only affect the ratio of the secreted peptides, but
can also increase the total production of bA4(1-42). The
results obtained with this ER-retained APP/KK mutant
also indicate that the clinical PS mutations are operating in
the ER. This conclusion was further corroborated in an ex-
periment comparing the amyloid peptide production from
APP/LDLR in control and PS1M146L hippocampal neu-
rons. As expected for a mutant trafficking mainly in the
endocytic compartments, a relative increase in secreted
bA4(1-40) of 2.3660.18 (n 5 3, SEM) fold was observed,
whereas secretion of bA4(1-42) remained largely unaf-
fected. Interestingly, the PS1M146L mutation did not cause a
statistically significant effect on the ratio of secreted bA4
peptides in these neurons. Finally, we note that in our ex-
perimental system, and for all APP constructs studied, PS1
clinical mutations do not cause a significant increase in the
bA4(1-42)/(1-40) ratio of intracellular peptides.
Discussion
In this study, we provide conclusive evidence that the bulk
of endogenously expressed PS1 in neurons is localized in
the early compartments of the secretory pathway, i.e., in
the ER, the IC, and the early Golgi. Relatively limited lev-
els of PS1 are furthermore detected in the nuclear enve-
lope and the RER. The ER, in contrast to the Golgi appa-
ratus, is widely distributed in the soma and the dendrites
(including the most distal regions) of neurons (Krijnse-
Locker et al., 1995). Therefore, our data explain the previ-
ously documented somatodendritic localization of the pre-
senilins (Cook et al., 1996; Busciglio et al., 1997; Capell et
al., 1997). Within these early compartments of the biosyn-
thetic pathway, a clear gradient of increasing amounts of
Figure 8. Processing of human wild-type APP (APPwt), the Lon-
don mutant (APP-Lon), and the APP sorting mutants, APPDCT,
APP/KK, and APP/LDLR in SFV-infected hippocampal neu-
rons. Immunoprecipitation of total bA4 from the culture super-
natant (MEDIUM) and carboxy-terminal b-stubs and total bA4
from the cell lysates (CELL) of metabolically labeled hippocam-
pal neurons using antibody B7/7 that recognizes an epitope on
the amino terminus of the bA4 sequence. Immunoprecipitates
were electrophoresed on 10–20% Tris-Tricine gels and analyzed
by phosphorimaging. Lower amounts of secreted bA4 are recov-
ered in the supernatants of cultures infected with APPDCT and
APP/KK as compared with the other virus constructs. Notice the
higher expression of APPDCT in the cell extracts. As expected,
infection with the SFV-APPDCT construct resulted in a shorter
carboxy-terminal b-stub. The contribution of carboxyl-terminal
fragments and bA4 from endogenous APP processing is neglect-
able as it is below detection level in untransfected cultures (No
Virus). Antibody B7/7 used for the bA4 immunoprecipitation ex-
periments reacts also with low affinity with APP-ectodomain, re-
covered in low quantities from the conditioned media (APPs).Annaert et al. Presenilin 1 Localization Versus APP Processing 289
the supposedly functional PS1 fragments is observed. The
PS1 immunoreactivity previously detected in the nuclear
membrane (Li et al., 1997) is, therefore, a mixture of (pre-
dominantly) PS1 fragments and full-length PS1, indicating
that cleavage of PS1 by the unknown presenilinase occurs
very early after biosynthesis (Xia et al., 1998). Impor-
tantly, these results definitively resolve the controversy
whether and where full-length presenilin can be detected,
namely in nuclear envelope fractions.
Interestingly, both the PS1-NTF and -CTF codistributed
and coenriched in all fractionation schemes applied, con-
firming at the endogenous level of protein expression that
both fragments remain in a 1:1 stoichiometric relationship
along the whole early biosynthetic pathway (Thinakaran
et al., 1996). Our data not only settle the debate on the
subcellular localization of presenilin, but also document
for the first time that PS1 immunoreactivity in the ER is
concentrated in discrete patches that are sec23p-positive.
Sec23p is one out of the five cytosolic proteins that consti-
tute the COPII coat complex required for vesicle budding
from the ER (Barlowe et al., 1994). These COPII compo-
nents bind specifically with cargo molecules destined for
Figure 9. Newly synthesized APP wild-type, but not
APP/KK, is sorted to axons in fully polarized hippocam-
pal neurons. (a) Double immunofluorescent staining for
APPwt (green) and calnexin (red). Newly expressed APP
was detected using a myc antibody. Infection with the
SFV-APPwt clearly resulted in axonal localization of the
expressed protein. (b) Newly expressed APP/KK was en-
tirely retained in the somatodendritic ER as demon-
strated by the virtual complete colocalization with cal-
nexin. APP and calnexin labeling were detected with
CY2 anti-mouse and lissamine rhodamine anti-rabbit
secondary antibodies, respectively. Asterisk marks a non-
transfected neuron. (c) Endogenous PS1 resides in mem-
brane-bound compartments involved in the trafficking
and retrieval of dilysine-tagged proteins. The newly ex-
pressed APP/KK (green) colocalizes with endogenous
PS1 (red) in polarized hippocampal neurons. The colo-
calization was most obvious in the somatic area (inset).
Detection of primary antibodies was with CY2 anti-
mouse (APP) and CY3 anti-rabbit (PS1-CTF) secondary
antibodies. Bars, 20 mm.The Journal of Cell Biology, Volume 147, 1999 290
sorting into transport vesicles and separate them from the
ER resident proteins (Campbell and Schekman, 1997; Ari-
dor et al., 1998; Kuehn et al., 1998). The formation of
COPII transport vesicles occurs nonrandomly in the ER at
tubular protrusions often juxtaposed to VTC, referred to
as the IC (Schweizer et al., 1990, 1991; Bannykh and
Balch, 1998). PS1 codistributes and coenriches with mark-
ers of this intriguing compartment such as p58/ERGIC-53
(Saraste and Svensson, 1991; Schweizer et al., 1991), sug-
gesting that PS1 is operating in these compartments. A
similar conclusion was recently made by Culvenor et al.
(1997) who, based on temperature block experiments, sug-
gested that PS1 is localized in the IC and cis-Golgi in sta-
bly transfected SY5Y and P19 cell lines. On the other
hand, and in contrast with many earlier studies investigat-
ing overexpressed PS1 (for instance De Strooper et al.,
1997), we could not confirm that PS1 at the endogenous
level of expression distributes to a significant extent into
the Golgi apparatus. This limits the subcellular compart-
ment where PS1 is operating to the early compartments of
the biosynthetic pathway. The earlier reported abundant
Golgi localization of the presenilins is probably a conse-
quence of overexpression and missorting of the protein.
As illustrated in Fig. 4 B, f and i, colocalization studies
should indeed be carefully interpreted. As we suggested
before (De Strooper et al., 1997), experiments based on
overexpression of presenilins may lead to erroneous con-
clusions since normal proteolytic maturation and also nor-
mal subcellular ER localization is apparently significantly
disturbed.
This conclusion is further corroborated by recent find-
ings that overexpression of presenilins results in their re-
distribution into aggresomes (Johnston et al., 1998). These
structures are located at the perinuclear microtubule orga-
nizing center, where also the Golgi apparatus is located
and are the signature of abnormal biosynthetic stress in
the cell. In view of our new data, it is conceivable that PS1
passes from the ER, via VTCs, to cis-Golgi cisternae. The
close colocalization of PS1 with sec23p further indicates
that at least part of this transport is associated with the
trafficking of COPII vesicles. (Schekman and Orci, 1996).
Since PS1 fragments exist as a stable complex with a long
half-life (Ratovitski et al., 1997) and no accumulation in
the Golgi apparatus was observed, PS1 is probably also
retrogradely transported. Electron microscopical observa-
tions demonstrating abundant PS1 immunoreactivity in
vesiculotubular structures and coated vesicles in close vi-
cinity or in continuity with Golgi cisternae support the
view that presenilins are actively transported back and for-
ward between the ER and cis-Golgi (Lah et al., 1997). The
lack of PS1 immunoreactivity in TGN-enriched fractions
(Fig. 4 A) suggests that only minimal amounts of PS1, if
any, exit the Golgi area. Indeed, no significant amounts of
PS1 were found in recycling endosomes, lysosomes, synap-
tic vesicles, or clathrin-coated vesicles (not shown and Ef-
thimiopoulos et al., 1998). Finally, all published data that
support the localization of PS1 at the plasma membrane
(Dewji and Singer, 1997; Schwarzman et al., 1999) imply a
topology of PS1 with the amino-terminal domain at the lu-
minal side of the ER. This is not in agreement with several
studies (Doan et al., 1996; Li and Greenwald, 1996; De
Strooper et al., 1997; Lehmann et al., 1997) that addressed
this question more specifically, although it could be specu-
lated that cell type–specific differences exist. In any event,
our data in hippocampal neurons clearly indicate that the
bulk of PS1 fragments are localized in compartments of
the early biosynthetic pathway and that only limited
amounts (if any at all) traffic beyond the Golgi apparatus,
a finding that needs to be taken into account when consid-
ering the association of presenilin with g- secretase activi-
ties.
Accumulating evidence indicate that presenilins are ei-
ther part of the catalytic g-secretase activity (Wolfe et al.,
1999) or at least controlling its activity (De Strooper et al.,
1998, 1999). Wolfe et al. (1999) presented evidence that
presenilins are aspartate proteases that become inacti-
vated by mutating one of the two aspartic acid residues in
the sixth or seventh transmembrane region respectively.
Overexpression of this mutant PS1 results in dominant
negative effects on g-secretase activity (Steiner et al., 1999;
Wolfe et al., 1999). The most simple explanation is that
PS1 is g-secretase itself. This interpretation is consistent
with the observation that deletion of the PS1 gene also re-
sults in the inhibition of g-secretase (De Strooper et al.,
1998, 1999). In both experiments, secretion of bA4(1-40)
as well as bA4(1-42) peptides was equally affected (De
Strooper et al., 1998; Wolfe et al., 1999). The subcellular
localization of PS1 in the ER as we demonstrate here, is,
however, difficult to reconcile with current concepts that
g-secretase processing of APP mainly occurs in the en-
docytic limb of the subcellular trafficking pathways.
There is clearly a spatial paradox. The first question to
be addressed in this regard is whether the real substrates
of g-secretase, namely the a- and b-secretase cleaved APP
carboxy-terminal stubs generally believed to be generated
in the late biosynthetic compartments and the endocytic
pathways, can indeed reach the subcellular compartments
where PS1 resides. Unexpectedly, we could demonstrate
the enrichment of the APP carboxy-terminal stubs in the
ER/IC subcellular fractions where PS1 resides. From a cell
biological point of view, it remains to be explained how
this retrograde transport of the APP carboxy-terminal
fragments to the ER/IC can occur and which sorting sig-
nals are involved, but this finding is at least consistent with
the PS1–g-secretase hypothesis (Wolfe et al., 1999). The
second question is whether and how PS1 can affect the
generation of amyloid peptide in the endocytic limb of
the protein trafficking pathways in the cell. This problem
was addressed via a functional approach by expressing a
series of APP trafficking mutants in hippocampal neurons
using the recombinant SFV system. In previous work, it
has been extensively demonstrated that the processing and
subcellular trafficking of APP expressed with this system
does not differ from that observed with endogenously ex-
pressed APP (De Strooper et al., 1995; Simons et al., 1995,
1996; Tienari et al., 1996a,b; Chyung et al., 1997). There-
fore, and in contrast with presenilins, the results obtained
after transfection of APP with SFV under the experimen-
tal conditions used, can be considered as biologically rele-
vant.
The results (see Table I) obtained with APP retained in
the ER (APP/KK), with APP processed in the biosyn-
thetic pathway (APPDCT) or with APP retrieved in the
endocytic pathway (APP/LDLR, not shown), corrobo-Annaert et al. Presenilin 1 Localization Versus APP Processing 291
rated the conclusion that presenilins operate in the ER/IC.
Significant increases in bA4(1-42) secretion were ob-
served with the APP/KK and to a lesser extent with the
APPDCT mutant in neurons expressing PS1M146L.. Such an
effect was almost undetectable with the APP/LDL mutant.
The latter most likely reflects the inability of the APP/
LDLR carboxy-terminal fragments generated by a- or
b-secretase to be recycled to compartments where g-secre-
tase resides. The APP/KK mutant was particular relevant
in this regard. The dilysine Golgi–ER retrieval signal is
recognized by COPI subunits in proteins such as p58/ER-
GIC-53 and results in their retrograde retrieval from
VTCs and cis-Golgi cisternae to the ER (Cosson and Le-
tourneur, 1994; Arar et al., 1995; Lahtinen et al., 1996;
Bannykh and Balch, 1997). The KK motif limits the traf-
ficking of APP/KK to those compartments where also PS1
resides. Indeed, the subcellular distribution of APP/KK
was strikingly similar to that of endogenous PS1 (Fig. 9).
As previously demonstrated, only very low amounts of
amyloid peptide are recovered in the media with this con-
struct (5% compared with wild-type APP). Since b-secre-
tase is mainly operating beyond the ER/IC (Higaki et al.,
1995; Chyung et al., 1997), it is not surprising that only
very small amounts of the immediate precursor of bA4,
i.e., the b-secretase cleaved carboxy-terminal APP frag-
ment (Paganetti et al., 1996; De Strooper et al., 1998), are
generated with APP/KK (Fig. 9). In contrast to the inter-
pretation of Chyung et al. (1997), we do not consider the
residual b-secretase activity as evidence for a novel, ER-
linked b-secretase activity. Since .95% of the normal
b-secretase activity is precluded with this construct, this
indicates in fact that b-secretase is operating mainly beyond
the cis-Golgi, and that APP/KK is only marginally pro-
cessed by enzyme trailing in the cis-Golgi. This interpreta-
tion is certainly more in line with general concepts of
b-secretase activity in other cell types since shown to de-
pend on the activity of Rab1B (Dugan et al., 1995) and on
O-glycosylation (Tomita et al., 1998). In any event, the re-
sidual generation of b-secretase cleaved fragments obtained
with APP/KK was sufficient to demonstrate that mainly
1-42 peptide is generated in ER, IC, and early cis-Golgi,
where the APP/KK carboxy-terminal stub is recycling.
More importantly, the presenilin mutants have a pro-
nounced effect on this process, which is clearly consistent
with their subcellular localization.
On the other hand, g40-secretase processing in the en-
docytic pathways is not at all influenced by the PS1 muta-
tions as was most dramatically illustrated with the APP/
LDLR mutant. The processing of this mutant, which se-
lectively increases the production and secretion of the
b4A(1-40) peptide (this study), was not altered by coex-
pression of the PS1M146L. It is generally accepted that the
bulk of the bA4(1-40) peptide is generated beyond the
TGN (Cook et al., 1997; Hartmann et al., 1997) and in
the endocytic pathways (Koo and Squazzo, 1994; Perez et
al., 1996, 1999; Peraus et al., 1997; Wild-Bode et al., 1997;
Greenfield et al., 1999) compartments where no PS1 is
found (this study). This explains why PS1 mutations have
no major effects on the secretion of bA4(1-40). Further
evidence for the selective effect of the presenilin muta-
tions on g-secretase cleavage at position 42 was obtained
when coexpressing APP-London together with mutant
PS1 (Borchelt et al., 1997; Citron et al., 1998; this study).
Both clinical mutations increase the bA4(1-42) secretion
and act additively, which suggests independent or at least
synergistic mechanisms operating with the two mutations.
The experimental evidence presented here together with
many reports in the literature suggests strongly an exclu-
sive role for the presenilins in g42-cleavage (as opposed to
g40 cleavage). The effect of the inactivation of PS1 (De
Strooper et al., 1998) or the expression of dominant nega-
tive forms of PS1 (Wolfe et al., 1999) on g40-secretase ac-
tivity must, therefore, be indirect. One possibility is a
precursor–product relationship between bA4(1-42) and
bA4(1-40). In this view, only one g-secretase is needed
that generates bA4(1-42), whereas in compartments distal
to the ER, carboxypeptidases convert this peptide to
bA4(1-40). This would explain the above-mentioned spa-
tial paradox, but not completely the selective increased se-
cretion of bA4(1-42) linked to PS1 clinical mutations. In a
precursor–product relationship, one should also expect a
rise in the secretion of bA4(1-40), and this has not been
really observed yet. Along similar lines, the fact that the
APP/LDLR or APPDCT mutations that affect APP traf-
ficking in the endocytic compartments have a direct effect
on bA4(1-40) production and secretion, support the gen-
eral importance of this pathway in APP processing, and
imply the existence of a g40-secretase activity in the en-
docytic limb. Therefore, it is clear that further investiga-
tions are needed to explain the relationship between PS1
and g40-secretase activity.
Unexpectedly, blocking the processing of APP in the en-
docytic pathway also decreases secretion of bA4(1-42)
(this study; Perez et al., 1999), whereas stimulating the
endocytic recycling (APP/LDLR) selectively promotes
bA4(1-40) secretion. A recent study provided evidence
that the cytoplasmic tail of APP contains, in addition to
endocytic signals, information that influences its metabo-
lism in the exocytotic limb (Perez et al., 1999).
Apart from the spatial paradox, it remains to be ex-
plained why mainly the immature, N-glycosylated form of
APP holoprotein has been found to interact physically
with PS1 (Weidemann et al., 1997; Xia et al., 1997). One
would predict a preferential association with the carboxy-
terminal APP fragments if PS1 was indeed g-secretase. It
could be speculated that PS1 is involved in a posttransla-
tional modification of the newly synthesized APP, tagging
it for later recognition by the g-secretases, although any
direct evidence supporting such a possibility is lacking.
Other hypotheses have been proposed as well. PS1 might
control trafficking of APP to its processing compartments,
or alternatively, control trafficking of the g-secretases to
APP-bearing compartments. For instance, the subtle ef-
fects on the maturation of TrkB and on BDNF-inducible
TrkB autophosphorylation caused by PS1 deficiency in
neurons was interpreted to reflect such a function (Naruse
et al., 1998). Our findings that endogenous PS1 colocalizes
with marker proteins of the IC and ER, would agree with a
recruiting or activating function for PS1, either as a chap-
erone or an adaptor molecule bringing g-secretase, APP
carboxy-terminal fragments, and maybe other substrates
(De Strooper et al., 1999) together in the right subcellular
microenvironment needed for the controlled and limited
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In conclusion, our data indicate clearly a direct role for
PS1 in g42-secretase activity in the early compartments of
the biosynthetic pathway. They are compatible with the
hypothesis that PS1 is g42-secretase, and imply that g42-
secretase exerts its activity in close association with trans-
port processes between ER and the cis-Golgi. However,
some caution with this straightforward interpretation re-
mains indicated, since several other observations remain
difficult to integrate with this concept, most notoriously
the relationship between PS1 deficiency and g40-secretase
processing. Therefore, the alternative possibilities dis-
cussed above have to be further explored, and further re-
search should clarify the exact molecular relationship be-
tween PS1 and g40- and g42-secretase activity.
The authors wish to thank E. Hartmann, A. Helenius, R. Jahn, J.-P. Pac-
caud, M. Reth, J. Saraste, I. Trowbridge, and G. Warren for their gifts of
polyclonal and monoclonal antibodies. We thank Dr. Philippe Cupers for
stimulating discussions, Vincent Schrijvers for his excellent technical sup-
port, and Prof. Dr. Fred Van Leuven for facilities and inimitable hospital-
ity. Lili Zhang (Department of CNS/Cardiovascular Research, Schering-
Plough Research Institute, NJ) is greatly acknowledged for processing all
bA4-ELISAs. 
W.G. Annaert is a postdoctoral fellow and B. De Strooper is a group
leader of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen
(F.W.O.). This work was financially supported by the Flanders Interuni-
versitary Institute for Biotechnology (VIB), the F.W.O., the I.U.A.P., and
the Human Frontier Science Program. D. Westaway, P. Fraser, and P. St.
George-Hyslop acknowledge the Medical Research Council of Canada,
the Alzheimer Society of Ontario, the Scottish Rite Charitable Founda-
tion, the EJLB Foundation and the Howard Hughes Medical Research
Foundation for providing the necessary financial support.
Submitted: 5 April 1999
Revised: 13 August 1999
Accepted: 6 September 1999
References
Annaert, W.G., B. Becker, U. Kistner, M. Reth, and R. Jahn. 1997. Export of
cellubrevin from the endoplasmic reticulum is controlled by BAP31. J. Cell
Biol. 139:1397–1410.
Arar, C., V. Carpentier, J.P. Le Caer, M. Monsigny, A. Legrand, and A.C.
Roche. 1995. ERGIC-53, a membrane protein of the endoplasmic reticulum-
Golgi intermediate compartment, is identical to MR60, an intracellular man-
nose-specific lectin of myelomonocytic cells. J. Biol. Chem. 270:3551–3553.
Aridor, M., J. Weissman, S. Bannykh, C. Nuoffer, and W.E. Balch. 1998. Cargo
selection by the COPII budding machinery during export from the ER. J.
Cell Biol. 141:61–70.
Bannykh, S.I., and W.E. Balch. 1997. Membrane dynamics at the endoplasmic
reticulum–Golgi interface. J. Cell Biol. 138:1–4.
Bannykh, S.I., and W.E. Balch. 1998. Selective transport of cargo between the
endoplasmic reticulum and Golgi compartments. Histochem. Cell Biol. 109:
463–475.
Barlowe, C., L. Orci, T. Yeung, M. Hosobuchi, S. Hamamoto, N. Salama, M.F.
Rexach, M. Ravazzola, M. Amherdt, and R. Schekman. 1994. COPII: a
membrane coat formed by Sec proteins that drive vesicle budding from the
endoplasmic reticulum. Cell. 77:895–907.
Baumeister, R., and C. Haass. 1998. Presenilin proteins and their role in devel-
opment and notch signaling. In Molecular Biology of Alzheimer’s Disease.
C. Haass, editor. Harwood Academic Publishers, Amsterdam. 219–234.
Borchelt, D.R., G. Thinakaran, C.B. Eckman, M.K. Lee, F. Davenport, T. Ra-
tovitsky, C.M. Prada, G. Kim, S. Seekins, D. Yager, et al. 1996. Familial
Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ra-
tio in vitro and in vivo. Neuron. 17:1005–1013.
Borchelt, D.R., T. Ratovitski, J. van Lare, M.K. Lee, V. Gonzales, N.A. Jen-
kins, N.G. Copeland, D.L. Price, and S.S. Sisodia. 1997. Accelerated amyloid
deposition in the brains of transgenic mice coexpressing mutant presenilin 1
and amyloid precursor proteins. Neuron. 19:939–945.
Brockhaus, M., J. Grunberg, S. Rohrig, H. Loetscher, N. Wittenburg, R.
Baumeister, H. Jacobsen, and C. Haass. 1998. Caspase-mediated cleavage is
not required for the activity of presenilins in amyloidogenesis and NOTCH
signaling. Neuroreport. 9:1481–1486.
Bu, G., and A.L. Schwartz. 1998. RAP, a novel type of ER chaperone. Trends
Cell Biol. 8:272–276.
Busciglio, J., H. Hartmann, A. Lorenzo, C. Wong, K. Baumann, B. Sommer, M.
Staufenbiel, and B.A. Yankner. 1997. Neuronal localization of presenilin-1
and association with amyloid plaques and neurofibrillary tangles in Alz-
heimer’s disease. J. Neurosci. 17:5101–5107.
Campbell, J.L., and R. Schekman. 1997. Selective packaging of cargo molecules
into endoplasmic reticulum-derived COPII vesicles. Proc. Natl. Acad. Sci.
USA. 94:837–842.
Capell, A., R. Saffrich, J.C. Olivo, L. Meyn, J. Walter, J. Grunberg, P. Mathews,
R. Nixon, C. Dotti, and C. Haass. 1997. Cellular expression and proteolytic
processing of presenilin proteins is developmentally regulated during neu-
ronal differentiation. J. Neurochem. 69:2432–2440.
Capell, A., J. Grunberg, B. Pesold, A. Diehlmann, M. Citron, R. Nixon, K. Bey-
reuther, D.J. Selkoe, and C. Haass. 1998. The proteolytic fragments of the
Alzheimer’s disease-associated presenilin-1 form heterodimers and occur as
a 100-150-kDa molecular mass complex. J. Biol. Chem. 273:3205–3211.
Chyung, A.S.C., B.D. Greenberg, D.G. Cook, R.W. Doms, and V.M. Lee. 1997.
Novel b-secretase cleavage of b-amyloid precursor protein in the endoplas-
mic reticulum/intermediate compartment of NT2N cells. J. Cell Biol. 138:
671–680.
Citron, M., D. Westaway, W. Xia, G. Carlson, T. Diehl, G. Levesque, K.
Johnson-Wood, M. Lee, P. Seubert, A. Davis, et al. 1997. Mutant presenilins
of Alzheimer’s disease increase production of 42-residue amyloid beta-pro-
tein in both transfected cells and transgenic mice. Nat. Med. 3:67–72.
Citron, M., C.B. Eckman, T.S. Diehl, C. Corcoran, B.L. Ostaszewski, W. Xia,
G. Levesque, P. St. George Hyslop, S.G. Younkin, and D.J. Selkoe. 1998.
Additive effects of PS1 and APP mutations on secretion of the 42-residue
amyloid beta-protein. Neurobiol. Dis. 5:107–116.
Cook, D.G., J.C. Sung, T.E. Golde, K.M. Felsenstein, B.S. Wojczyk, R.E.
Tanzi, J.Q. Trojanowski, V.M. Lee, and R.W. Doms. 1996. Expression and
analysis of presenilin 1 in a human neuronal system: localization in cell bod-
ies and dendrites. Proc. Natl. Acad. Sci. USA. 93:9223–9228.
Cook, D.G., M.S. Forman, J.C. Sung, S. Leight, D.L. Kolson, T. Iwatsubo, V.M.
Lee, and R.W. Doms. 1997. Alzheimer’s A beta(1-42) is generated in the en-
doplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med.
3:1021–1023.
Cosson, P., and F. Letourneur. 1994. Coatomer interaction with di-lysine endo-
plasmic reticulum retention motifs. Science. 263:1629–1631.
Culvenor, J.G., F. Maher, G. Evin, F. Malchiodi-Albedi, R. Cappai, J.R. Un-
derwood, J.B. Davis, E.H. Karran, G.W. Roberts, K. Beyreuther, and C.L.
Masters. 1997. Alzheimer’s disease-associated presenilin 1 in neuronal cells:
evidence for localization to the endoplasmic reticulum-Golgi intermediate
compartment. J. Neurosci. Res. 49:719–731.
De Strooper, B., L. Umans, F. Van Leuven, and H. Van Den Berghe. 1993.
Study of the synthesis and secretion of normal and artificial mutants of mu-
rine amyloid precursor protein (APP): cleavage of APP occurs in a late com-
partment of the default secretion pathway. J. Cell Biol. 121:295–304.
De Strooper, B., M. Simons, G. Multhaup, F. Van Leuven, K. Beyreuther, and
C.G. Dotti. 1995. Production of intracellular amyloid-containing fragments
in hippocampal neurons expressing human amyloid precursor protein and
protection against amyloidogenesis by subtle amino acid substitutions in the
rodent sequence. EMBO (Eur. Mol. Biol. Organ.) J. 14:4932–4938.
De Strooper, B., M. Beullens, B. Contreras, L. Levesque, K. Craessaerts, B.
Cordell, D. Moechars, M. Bollen, P. Fraser, P.S. George-Hyslop, and F. Van
Leuven. 1997. Phosphorylation, subcellular localization, and membrane ori-
entation of the Alzheimer’s disease-associated presenilins. J. Biol. Chem.
272:3590–3598.
De Strooper, B., P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, W.
Annaert, K. Von Figura, and F. Van Leuven. 1998. Deficiency of presenilin-1
inhibits the normal cleavage of amyloid precursor protein. Nature. 391:387–
390.
De Strooper, B., W. Annaert, P. Cupers, P. Saftig, K. Craessaerts, J.S. Mumm,
E.H. Schroeter, V. Schrijvers, M.S. Wolfe, W.J. Ray, A. Goate, and R. Ko-
pan. 1999. A presenilin-1-dependent, gamma-secretase-like protease medi-
ates release of Notch intracellular domain. Nature. 398:518–522.
Dewji, N.N., and S.J. Singer. 1997. Cell surface expression of the Alzheimer dis-
ease-related presenilin proteins. Proc. Natl. Acad. Sci. USA. 94:9926–9931.
Doan, A., G. Thinakaran, D.R. Borchelt, H.H. Slunt, T. Ratovitsky, M.
Podlisny, D.J. Selkoe, M. Seeger, S.E. Gandy, D.L. Price, and S.S. Sisodia.
1996. Protein topology of presenilin 1. Neuron. 17:1023–1030.
Duff, K., C. Eckman, C. Zehr, X. Yu, C.M. Prada, J. Perez-tur, M. Hutton, L.
Buee, Y. Harigaya, D. Yager, D. Morgan, M.N. Gordon, et al. 1996. In-
creased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.
Nature. 383:710–713.
Dugan, J.M., C. de Wit, L. McConlogue, and W.A. Maltese. 1995. The Ras-
related GTP-binding protein, Rab1B, regulates early steps in exocytic trans-
port and processing of beta-amyloid precursor protein. J. Biol. Chem. 270:
10982–10989.
Efthimiopoulos, S., E. Floor, A. Georgakopoulos, J. Shioi, W. Cui, S. Ya-
sothornsrikul, V.Y. Hook, T. Wisniewski, L. Buee, and N.K. Robakis. 1998.
Enrichment of presenilin 1 peptides in neuronal large dense-core and soma-
todendritic clathrin-coated vesicles. J. Neurochem. 71:2365–2372.
Evan, G.I., G.K. Lewis, G. Ramsay, and J.M. Bishop. 1985. Isolation of mono-
clonal antibodies specific for human c-myc proto-oncogene product. Mol.
Cell Biol. 5:3610–3616.
Gorlich, D., S. Prehn, E. Hartmann, K.U. Kalies, and T.A. Rapoport. 1992. AAnnaert et al. Presenilin 1 Localization Versus APP Processing 293
mammalian homolog of SEC61p and SECYp is associated with ribosomes
and nascent polypeptides during translocation. Cell. 71:489–503.
Goslin, K., and G.A. Banker. 1991. Rat hippocampal neurons in low density
culture. In Culturing Nerve Cells. G.A. Banker and K. Goslin, editors. MIT
Press, Cambridge, MA. 251–281.
Greenfield, J.P., J. Tsai, G.K. Gouras, B. Hai, G. Thinakaran, F. Checler, S.S.
Sisodia, P. Greengard, and H. Xu. 1999. Endoplasmic reticulum and trans-
Golgi network generate distinct populations of alzheimer beta-amyloid pep-
tides. Proc. Natl. Acad. Sci. USA. 96:742–747.
Haass, C., and D.J. Selkoe. 1993. Cellular processing of beta-amyloid precursor
protein and the genesis of amyloid beta-peptide. Cell. 75:1039–1042.
Haass, C., C.A. Lemere, A. Capell, M. Citron, P. Seubert, D. Schenk, L. Lann-
felt, and D.J. Selkoe. 1995. The Swedish mutation causes early-onset Alz-
heimer’s disease by beta-secretase cleavage within the secretory pathway.
Nat. Med. 1:1291–1296.
Hartmann, E., D. Gorlich, S. Kostka, A. Otto, R. Kraft, S. Knespel, E. Burger,
T.A. Rapoport, and S. Prehn. 1993. A tetrameric complex of membrane pro-
teins in the endoplasmic reticulum. Eur. J. Biochem. 214:375–381.
Hartmann, T., S.C. Bieger, B. Bruhl, P.J. Tienari, N. Ida, D. Allsop, G.W. Rob-
erts, C.L. Masters, C.G. Dotti, K. Unsicker, and K. Beyreuther. 1997. Dis-
tinct sites of intracellular production for Alzheimer’s disease A beta40/42
amyloid peptides. Nat. Med. 3:1016–1020.
Higaki, J., D. Quon, Z. Zhong, and B. Cordell. 1995. Inhibition of beta-amyloid
formation identifies proteolytic precursors and subcellular site of catabo-
lism. Neuron. 14:651–659.
Johnston, J.A., C.L. Ward, and R.R. Kopito. 1998. Aggresomes: a cellular re-
sponse to misfolded proteins. J. Cell Biol. 143:1883–1898.
Klumperman, J., A. Schweizer, H. Clausen, B.L. Tang, W. Hong, V. Oorschot,
and H.P. Hauri. 1998. The recycling pathway of protein ERGIC-53 and dy-
namics of the ER-Golgi intermediate compartment. J Cell Sci. 111:3411–
3425.
Koo, E.H., and S.L. Squazzo. 1994. Evidence that production and release of
amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269:
17386–17389.
Kovacs, D.M., H.J. Fausett, K.J. Page, T.W. Kim, R.D. Moir, D.E. Merriam,
R.D. Hollister, O.G. Hallmark, R. Mancini, K.M. Felsenstein, B.T. Hyman,
R.E. Tanzi, and W. Wasco. 1996. Alzheimer-associated presenilins 1 and 2:
neuronal expression in brain and localization to intracellular membranes in
mammalian cells. Nat. Med. 2:224–229.
Krijnse-Locker, J., R.G. Parton, S.D. Fuller, G. Griffiths, and C.G. Dotti. 1995.
The organization of the endoplasmic reticulum and the intermediate com-
partment in cultured rat hippocampal neurons. Mol. Biol. Cell. 6:1315–1332.
Kuehn, M.J., J.M. Herrmann, and R. Schekman. 1998. COPII-cargo interac-
tions direct protein sorting into ER-derived transport vesicles. Nature. 391:
187–190.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature. 227:680–685.
Lah, J.J., C.J. Heilman, N.R. Nash, H.D. Rees, H. Yi, S.E. Counts, and A.I.
Levey. 1997. Light and electron microscopic localization of presenilin-1 in
primate brain. J. Neurosci. 17:1971–1980.
Lahtinen, U., U. Hellman, C. Wernstedt, J. Saraste, and R.F. Pettersson. 1996.
Molecular cloning and expression of a 58-kDa cis-Golgi and intermediate
compartment protein. J. Biol. Chem. 271:4031–4037.
Lehmann, S., R. Chiesa, and D.A. Harris. 1997. Evidence for a six-transmem-
brane domain structure of presenilin 1. J. Biol. Chem. 272:12047–12051.
Levesque, L., W. Annaert, K. Craessaert, P.M. Mathews, M. Seeger, R.A.
Nixon, F. Van Leuven, S. Gandy, D. Westaway, P. St. George-Hyslop, B. De
Strooper, and P.E. Fraser. 1999. Developmental expression of wild-type and
mutant presenilin-1 in hippocampal neurons from transgenic mice: evidence
for novel species-specific properties of human presenilin-1. Mol. Med. In
press.
Levey, A.I., C.J. Heilman, J.J. Lah, N.R. Nash, H.D. Rees, M. Wakai, S.S.
Mirra, D.B. Rye, D. Nochlin, T.D. Bird, and E.J. Mufson. 1997. Presenilin-1
protein expression in familial and sporadic Alzheimer’s disease. Ann. Neu-
rol. 41:742–753.
Levitan, D., and I. Greenwald. 1995. Facilitation of lin-12-mediated signalling
by sel-12, a Caenorhabditis elegans S182 Alzheimer’s disease gene. Nature.
377:351–354.
Levy-Lahad, E., W. Wasco, P. Poorkaj, D.M. Romano, J. Oshima, W.H. Pettin-
gell, C.E. Yu, P.D. Jondro, S.D. Schmidt, K. Wang, et al. 1995. Candidate
gene for the chromosome 1 familial Alzheimer’s disease locus [see com-
ments]. Science. 269:973–977.
Li, J., M. Xu, H. Zhou, J. Ma, and H. Potter. 1997. Alzheimer presenilins in the
nuclear membrane, interphase kinetochores, and centrosomes suggest a role
in chromosome segregation. Cell. 90:917–927.
Li, X., and I. Greenwald. 1996. Membrane topology of the C. elegans SEL-12
presenilin. Neuron. 17:1015–1021.
Li, X., and I. Greenwald. 1998. Additional evidence for an eight-transmem-
brane-domain topology for Caenorhabditis elegans and human presenilins.
Proc. Natl. Acad. Sci. USA. 95:7109–7114.
Liljestrom, P., and H. Garoff. 1991. A new generation of animal cell expression
vectors based on the Semliki Forest virus replicon. Biotechnology. 9:1356–
1361.
Maguire, G.A., and J.P. Luzio. 1985. The presence and orientation of ecto-59-
nucleotidase in rat liver lysosomes. FEBS (Fed. Eur. Biochem. Soc.) Lett.
180:122–126.
Mercken, M., H. Takahashi, T. Honda, K. Sato, M. Murayama, Y. Nakazato, K.
Noguchi, K. Imahori, and A. Takashima. 1996. Characterization of human
presenilin 1 using N-terminal specific monoclonal antibodies: evidence that
Alzheimer mutations affect proteolytic processing. FEBS (Fed. Eur. Bio-
chem. Soc.) Lett. 389:297–303.
Naruse, S., G. Thinakaran, J.J. Luo, J.W. Kusiak, T. Tomita, T. Iwatsubo, X.
Qian, D.D. Ginty, D.L. Price, D.R. Borchelt, P.C. Wong, and S.S. Sisodia.
1998. Effects of PS1 deficiency on membrane protein trafficking in neurons.
Neuron. 21:1213–1221.
Olkkonen, V.M., P. Liljestrom, H. Garoff, K. Simons, and C.G. Dotti. 1993. Ex-
pression of heterologous proteins in cultured rat hippocampal neurons using
the Semliki Forest virus vector. J. Neurosci. Res. 35:445–451.
Otto, H., K. Buchner, R. Beckmann, R. Hilbert, and F. Hucho. 1992. GTP-
binding proteins in bovine brain nuclear membranes. Neurochem Int. 21:
409–414.
Paganetti, P.A., M. Lis, H.W. Klafki, and M. Staufenbiel. 1996. Amyloid pre-
cursor protein truncated at any of the gamma-secretase sites is not cleaved
to beta-amyloid. J. Neurosci. Res. 46:283–293.
Peraus, G.C., C.L. Masters, and K. Beyreuther. 1997. Late compartments of
amyloid precursor protein transport in SY5Y cells are involved in beta-amy-
loid secretion. J. Neurosci. 17:7714–7724.
Perez, R.G., S.L. Squazzo, and E.H. Koo. 1996. Enhanced release of amyloid
beta-protein from codon 670/671 “Swedish” mutant beta-amyloid precursor
protein occurs in both secretory and endocytic pathways. J. Biol. Chem. 271:
9100–9107.
Perez, R.G., S. Soriano, J.D. Hayes, B. Ostaszewski, W. Xia, D.J. Selkoe, X.
Chen, G.B. Stokin, and E.H. Koo. 1999. Mutagenesis identifies new signals
for beta-amyloid precursor protein endocytosis, turnover, and the genera-
tion of secreted fragments, including abeta42. J. Biol. Chem. 274:18851–
18856.
Ratovitski, T., H.H. Slunt, G. Thinakaran, D.L. Price, S.S. Sisodia, and D.R.
Borchelt. 1997. Endoproteolytic processing and stabilization of wild-type
and mutant presenilin. J. Biol. Chem. 272:24536–24541.
Rogaev, E.I., R. Sherrington, E.A. Rogaeva, G. Levesque, M. Ikeda, Y. Liang,
H. Chi, C. Lin, K. Holman, T. Tsuda, et al. 1995. Familial Alzheimer’s dis-
ease in kindreds with missense mutations in a gene on chromosome 1 related
to the Alzheimer’s disease type 3 gene. Nature. 376:775–778.
Sambamurti, K., L.M. Refolo, J. Shioi, M.A. Pappolla, and N.K. Robakis. 1992.
The Alzheimer’s amyloid precursor is cleaved intracellularly in the trans-
Golgi network or in a post-Golgi compartment. Ann. NY. Acad. Sci. 674:
118–128.
Saraste, J., and K. Svensson. 1991. Distribution of the intermediate elements
operating in ER to Golgi transport. J. Cell Sci. 100:415–430.
Schekman, R., and L. Orci. 1996. Coat proteins and vesicle budding. Science.
271:1526–1533.
Scheuner, D., C. Eckman, M. Jensen, X. Song, M. Citron, N. Suzuki, T.D. Bird,
J. Hardy, M. Hutton, W. Kukull, et al. 1996. Secreted amyloid beta-protein
similar to that in the senile plaques of Alzheimer’s disease is increased in
vivo by the presenilin 1 and 2 and APP mutations linked to familial Alz-
heimer’s disease. Nat. Med. 2:864–870.
Schwarzman, A.L., N. Singh, M. Tsiper, L. Gregori, A. Dranovsky, M.P. Vitek,
C.G. Glabe, P.H. St. George-Hyslop, and D. Goldgaber. 1999. Endogenous
presenilin 1 redistributes to the surface of lamellipodia upon adhesion of ju-
rkat cells to a collagen matrix. Proc. Natl. Acad. Sci. USA. 96:7932–7937.
Schweizer, A., J.A. Fransen, K. Matter, T.E. Kreis, L. Ginsel, and H.P. Hauri.
1990. Identification of an intermediate compartment involved in protein
transport from endoplasmic reticulum to Golgi apparatus. Eur. J. Cell Biol.
53:185–196.
Schweizer, A., K. Matter, C.M. Ketcham, and H.P. Hauri. 1991. The isolated
ER–Golgi intermediate compartment exhibits properties that are different
from ER and cis-Golgi. J. Cell Biol. 113:45–54.
Selkoe, D.J. 1998. The cell biology of beta-amyloid precursor protein and pre-
senilin in Alzheimer’s disease. Trends Cell Biol. 8:447–453.
Sherrington, R., E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, M. Ikeda,
H. Chi, C. Lin, G. Li, K. Holman, et al. 1995. Cloning of a gene bearing mis-
sense mutations in early-onset familial Alzheimer’s disease. Nature. 375:754–
760.
Simons, M., E. Ikonen, P.J. Tienari, A. Cid-Arregui, U. Monning, K. Bey-
reuther, and C.G. Dotti. 1995. Intracellular routing of human amyloid pro-
tein precursor: axonal delivery followed by transport to the dendrites. J.
Neurosci. Res. 41:121–128.
Simons, M., B. De Strooper, G. Multhaup, P.J. Tienari, C.G. Dotti, and K. Bey-
reuther. 1996. Amyloidogenic processing of the human amyloid precursor
protein in primary cultures of rat hippocampal neurons. J. Neurosci. 16:899–
908.
Sisodia, S.S. 1992. Beta-amyloid precursor protein cleavage by a membrane-
bound protease. Proc. Natl. Acad. Sci. USA. 89:6075–6079.
Steiner, H., K. Duff, A. Capell, H. Romig, M.G. Grim, S. Lincoln, J. Hardy, X.
Yu, M. Picciano, K. Fechteler, et al. 1999. A loss of function mutation of pre-
senilin-2 interferes with amyloid b-peptide production and notch signaling.
J. Biol. Chem. In press.
Thinakaran, G., D.R. Borchelt, M.K. Lee, H.H. Slunt, L. Spitzer, G. Kim, T.
Ratovitsky, F. Davenport, C. Nordstedt, M. Seeger, et al. 1996. Endopro-
teolysis of presenilin 1 and accumulation of processed derivatives in vivo.The Journal of Cell Biology, Volume 147, 1999 294
Neuron. 17:181–190.
Thinakaran, G., C.L. Harris, T. Ratovitski, F. Davenport, H.H. Slunt, D.L.
Price, D.R. Borchelt, and S.S. Sisodia. 1997. Evidence that levels of preseni-
lins (PS1 and PS2) are coordinately regulated by competition for limiting
cellular factors. J. Biol. Chem. 272:28415–28422.
Thinakaran, G., and S. Sisodia. 1998. The molecular biology of presenilin 1. In
Molecular Biology of Alzheimer’s Disease. C. Haass, editor. Harwood Aca-
demic Publishers, Amsterdam. 193–206.
Tienari, P.J., B. De Strooper, E. Ikonen, N. Ida, M. Simons, C.L. Masters, C.G.
Dotti, and K. Beyreuther. 1996a. Neuronal sorting and processing of amy-
loid precursor protein: implications for Alzheimer’s disease. Cold Spring
Harbor Symp. Quant. Biol. 61:575–585.
Tienari, P.J., B. De Strooper, E. Ikonen, M. Simons, A. Weidemann, C. Czech,
T. Hartmann, N. Ida, G. Multhaup, C.L. Masters, F. Van Leuven, K. Bey-
reuther, and C.G. Dotti. 1996b. The beta-amyloid domain is essential for ax-
onal sorting of amyloid precursor protein. EMBO (Eur. Mol. Biol. Organ.)
J. 15:5218–5229.
Tomita, S., Y. Kirino, and T. Suzuki. 1998. Cleavage of Alzheimer’s amyloid
precursor protein (APP) by secretases occurs after O-glycosylation of APP
in the protein secretory pathway. Identification of intracellular compart-
ments in which APP cleavage occurs without using toxic agents that inter-
fere with protein metabolism. J. Biol. Chem. 273:6277–6284.
Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of pro-
teins from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc. Natl. Acad. Sci. USA. 76:4350–4354.
Weidemann, A., K. Paliga, U. Durrwang, C. Czech, G. Evin, C.L. Masters, and
K. Beyreuther. 1997. Formation of stable complexes between two Alz-
heimer’s disease gene products: presenilin-2 and beta-amyloid precursor
protein.  Nat. Med. 3:328–332.
Wild-Bode, C., T. Yamazaki, A. Capell, U. Leimer, H. Steiner, Y. Ihara, and C.
Haass. 1997. Intracellular generation and accumulation of amyloid beta-pep-
tide terminating at amino acid 42. J. Biol. Chem. 272:16085–16088.
Wolfe, M.S., W. Xia, B.L. Ostaszewski, T.S. Diehl, W.T. Kimberly, and D.J.
Selkoe. 1999. Two transmembrane aspartates in presenilin-1 required for
presenilin endoproteolysis and gamma-secretase activity. Nature. 398:513–
517.
Xia, W., J. Zhang, R. Perez, E.H. Koo, and D.J. Selkoe. 1997. Interaction be-
tween amyloid precursor protein and presenilins in mammalian cells: impli-
cations for the pathogenesis of Alzheimer disease. Proc. Natl. Acad. Sci.
USA. 94:8208–8213.
Xia, W., J. Zhang, B.L. Ostaszewski, W.T. Kimberly, P. Seubert, E.H. Koo, J.
Shen, and D.J. Selkoe. 1998. Presenilin 1 regulates the processing of beta-
amyloid precursor protein C-terminal fragments and the generation of amy-
loid beta-protein in endoplasmic reticulum and Golgi. Biochemistry. 37:
16465–16471.
Yamazaki, T., D.J. Selkoe, and E.H. Koo. 1995. Trafficking of cell surface
b-amyloid precursor protein: retrograde and transcytotic transport in cul-
tured neurons. J. Cell Biol. 129:431–442.
Zhang, L., L. Song, and E.M. Parker. 1999. Calpain inhibitor I increases beta-
amyloid peptide production by inhibiting the degradation of the substrate of
gamma-secretase. Evidence that substrate availability limits beta-amyloid
peptide production. J. Biol. Chem. 274:8966–8972.